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SUMMARY  
 
Clusterin (CLU), also known as Apolipoprotein J, is a glycoprotein that has 
been implicated in various cell functions involved in carcinogenesis and 
tumour progression. There are two known CLU protein isoforms generated in 
human cells. The nuclear form of the CLU protein (nCLU) is proapoptotic, 
whereas the secretory form (sCLU) has pro-survival functions. sCLU up-
regulation appears to be a general molecular stress response. CLU 
expression has been associated with tumorigenesis of various malignancies, 
including human tumours of the prostate, colon, and breast. CLU expression 
is modulated by many factors that are involved in carcinogenesis or that 
regulate tumour growth and/or apoptosis, including 1,25-dihydroxyvitamin D3 
[1,25(OH)2D3], transforming growth factor beta-1, ultraviolet radiation, and 
ionizing radiation. However, the contribution of CLU signalling pathways for 
the UV-induced photocarcinogenesis of malignant melanoma, and for its 
progression and therapeutic outcome are still unknown. Presently, preliminary 
results in prostate cancer indicate that therapeutic modalities targeting CLU 
may be effective in cancer treatment. It was the aim of this study to gain 
further insights in the role of CLU in malignant melanoma and prostate cancer.  
 
First, CLU expression was studied immunohistochemically in paraffin sections 
of primary cutaneous malignant melanomas (n= 18), metastases of malignant 
melanoma (n= 25), and acquired melanocytic nevi (n= 30). We developed an 
immunoreactivity score (IRS) to characterize the intracellular localization of 
CLU and the expression pattern of CLU during the progression of malignant 
melanoma. 
In contrast to acquired melanocytic nevi, CLU immunoreactivity was detected 
in human primary cutaneous malignant melanomas (5 cases out of 18) and 
metastases of malignant melanomas (3 cases out of 20) in situ. The staining 
of the tissues was homogeneous (in the nuclei and cytoplasm of positive 
cells). The IRS score for malignant melanoma tissues (0.18) was higher than 
that for metastases of malignant melanomas (0.014). 
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Data reported in the literature indicate that expression of CLU may be directly 
regulated by 1,25(OH)2D3, an agent that induces apoptosis in melanoma cells 
and that is discussed to be of therapeutic use in the treatment of malignant 
melanoma. We therefore investigated CLU expression along with 
1,25(OH)2D3 treatment in vitamin D-sensitive (MeWo, SK-MEL-28) and -
resistant melanoma cell lines (SK-MEL-5, -25), as well as in normal human 
melanocytes (NHM), using conventional and real-time RT-PCR, and western 
blot. It was important to test for any differences in CLU expression depending 
on the kind of the melanoma cell line. 
Both the CLU protein and the corresponding mRNA were detected in all 
melanoma cell lines and NHM investigated, with varying expression levels. 
Real-time RT-PCR showed that vitamin D-resistant human melanoma cell 
lines had a higher basal level of CLU expression (7.5 x 10-3 of normalized 
ratio) as compared to -sensitive human melanoma cell lines (2.8 x 10-4 of 
normalized ratio). NHM had an expression level similar to that of vitamin D-
sensitive melanoma cell lines (2 x 10-4 of normalized ratio). In western blot 
analyses, only sCLU was detected in all melanoma cell lines and NHM 
analyzed. This sCLU protein expression was comparable to that of the mRNA 
where vitamin D-resistant melanoma cell lines showed stronger bands 
compared to -sensitive melanoma cell lines. We confirmed that vitamin D-
sensitive cell lines revealed anti-proliferative effects when treated with 
1,25(OH)2D3 (60% inhibition of cell proliferation in MeWo after 7 days of 
1,25(OH)2D3 treatment, 10
-6 M). Following 1,25(OH)2D3 treatment, one out of 
the two vitamin D-sensitive human melanoma cell lines analyzed (MeWo), 
showed an up-regulation in CLU mRNA expression after 96 hrs (1.5 fold 
increase at 10-6 M, p< 0.1). In contrast, the vitamin D-resistant melanoma cell 
line investigated (SK-MEL-5) showed no regulation of CLU expression along 
with 1,25(OH)2D3 treatment (10
-6 M, p > 1).  
 
Next, we analyzed whether changes in the expression of CLU modulate 
proapoptotic or anti-proliferative effects of 1,25(OH)2D3 or UV-B.  Treatment 
with 1,25(OH)2D3 is discussed as a potential therapy for metastasizing 
melanoma, while solar UV-B radiation is involved in pathogenesis of 
malignant melanoma. To address this question, we used a cell culture model 
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with human LNCaP prostate cancer cells. These cells were either stably 
transfected by exogenous transfection and over-express sCLU (LNT-1), or 
were stably transfected with the vector alone (LN/C) and express sCLU at a 
similar level as compared to the isogenic LNCaP cells. The antiproliferative 
effects of 1,25(OH)2D3 (10
-6, 10-7, or 10-10 M) or UV-B (0, 100, or 500 J/m2) on 
LNT-1 as compared to LN/C were evaluated using colony forming ability 
assays. Apoptotic responses following treatment with different doses of 
1,25(OH)2D3  or UV-B were measured using TUNEL assay.   
sCLU over-expression slightly protected LNCaP prostate cancer cells dose-
dependently against both anti-proliferative and proapoptotic effects of 
1,25(OH)2D3. This effect was most significant at a 1,25(OH)2D3-concentration 
of 10-7 M (30% protection, p< 0.1, against the anti-proliferative effects and 
approximately 12% protection, p< 0.1, against the proapoptotic effects). 
Interestingly, sCLU over-expression protected against the proapoptotic 
(approximately 16%, p= 0.038) but not the anti-proliferative (approximately 
0%, p> 0.1) effects following UV-B treatment. As investigated by the FACS 
analysis, sCLU over-expression did not affect the cell cycle of LNCaP cells 
following treatment either with 1,25(OH)2D3 or UV-B. 
 
CLU constitutive expression, and changes in expression after cell stress, 
could be of great importance for the growth regulation of human malignant 
melanoma and human prostate cancer, and could be involved in 1,25(OH)2D3 
apoptotic pathways. Moreover, our findings indicate that CLU may be of 
importance for the pathogenesis, progression and therapeutic outcome in 
these malignancies.  
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ZUSAMMENFASSUNG  
 
Das Glykoprotein Clusterin (CLU), auch bekannt als Apolipoprotein J, reguliert 
zahlreiche Zellfunktionen, die an Tumorentstehung und Tumorprogression 
beteiligt sind. In menschlichen Zellen sind zwei unterschiedliche Isoformen 
des CLU Proteins bekannt. Die nukleäre Form des CLU Proteins (nCLU) 
vermittelt proapoptotische Eigenschaften, wogegen die sekretorische Form 
(sCLU) zytoprotektive Funktionen ausübt. Die vermehrte Expression von 
sCLU ist wahrscheinlich ein wichtiger molekularer Mechanismus der 
zellulären Stressantwort. Die Expression von CLU wurde mit der Pathogenese 
zahlreicher Malignome, einschließlich Prostata-, Kolon- und Mammakarzinom 
assoziiert. Die Expression von CLU wird durch zahlreiche Faktoren, die auch 
für Tumorentstehung, Tumorprogression oder Apoptose von Bedeutung sind, 
moduliert. Hierzu zählen z.B. 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], 
Transforming growth factor beta-1, ultraviolette und ionisierende Strahlung. 
Die Beteiligung von CLU Signaltransduktionswegen an der 
Photokarzinogenese des malignen Melanoms, sowie an dessen Progression 
und therapeutischem Ansprechen, ist bislang jedoch noch völlig ungeklärt. 
Aktuell deuten erste Untersuchungsergebnisse beim Prostatakarzinom darauf 
hin, dass CLU eine interessante Zielstruktur zur Etablierung neuer 
Therapiemodalitäten darstellt. Die Zielsetzung dieser Arbeit bestand darin, 
neue Erkenntnisse über die Bedeutung von CLU beim malignen Melanom und 
beim Prostatakarzinom zu gewinnen 
 
Hierzu untersuchten wir zunächst immunhistochemisch die Expression von 
CLU in Paraffinschnitten von primär kutanen malignen Melanomen (n= 18), 
von Melanommetastasen (n= 25), und von erworbenen melanozytären Nävi 
(n= 30). Um die intrazelluläre Lokalisation von CLU und dessen 
Expressionsmuster während der Progression des malignen Melanom zu 
charakterisieren entwickelten wir einen Immunreaktivitätsscore (IRS).  
Im Gegensatz zu gutartigen melanozytären Nävi konnten wir eine CLU 
Immunreaktivität in primär kutanen malignen Melanomen (5 von 18 
untersuchten Präparaten) und in Melanommetastasen (3 von 20 Präparaten) 
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in situ nachweisen. In positiven Zellen zeigte sich eine homogene Markierung 
im Kern und im Zytoplasma. Bei den malignen Melanomen war der 
Immunreaktivitätsscore (0,18) höher, verglichen mit Melanommetastasen 
(0.014). 
 
Literaturdaten deuten darauf hin, daß die CLU Expression möglicherweise 
durch 1,25(OH)2D3 direkt reguliert wird, eine Substanz die in Melanomzellen 
Apoptose induziert und deren therapeutischer Einsatz beim malignen 
Melanom diskutiert wird. Deshalb untersuchten wir die CLU Expression in 
1,25(OH)2D3-behandelten Vitamin D-sensitiven (MeWo, SK-MEL-28) und -
resistenten Melanomzelllinien (SK-MEL-5, -25), und in normalen humanen 
Melanozyten (NHM). Hierzu wurden neben der konventionellen PCR auch die 
sogenannte real-time PCR sowie der Western Blot eingesetzt. 
Sowohl das CLU Protein als auch die korrespondierende mRNA konnten in 
allen untersuchten Melanomzelllinien und in NHM in unterschiedlicher 
Intensität  nachgewiesen werden. In der real-time RT-PCR zeigte sich, daß 
Vitamin D-resistente Melanomzelllinien eine höhere basale CLU Expression 
(7.5 x 10-3 des normalisierten Quotienten) aufweisen, verglichen mit –
sensitiven Melanomzelllinien (2.8 x 10-4 des normalisierten Quotienten). Die 
CLU Expression in NHM (2 x 10-4 des normalisierten Quotienten) war 
vergleichbar mit der in Vitamin D-sensitiven Melanomzelllinien. Im Western 
Blot wurde ausschließlich sCLU in Melanomzelllinien und in NHM 
nachgewiesen. Diese sCLU Protein Expression war vergleichbar mit der 
mRNA Expression. Vitamin D-resistenten Melanomzelllinien zeigten im 
Western Blot stärkere Banden als Vitamin D-sensitive Zelllinien. Wir 
bestätigten die antiproliferative Wirkung von 1,25(OH)2D3 auf Vitamin D-
sensitive Zelllinien (60%ige Hemmung der Proliferation von MeWo nach 7 
tägiger Behandlung mit 1,25(OH)2D3, 10
-6 M). Eine 96-stündige Behandlung 
mit 1,25(OH)2D3 (10
-6 M) führte in einer der beiden untersuchten Vitamin D-
sensitiven Melanomzellinien (MeWo) zu einer vermehrten CLU mRNA 
Expression (1.5 facher Anstieg, p< 0.1). Dieser Anstieg der CLU Expression 
nach 96-stündiger Behandlung mit 1,25(OH)2D3 (10
-6 M) fand sich nicht (p > 
1) in SK-MEL-5, der einzigen untersuchten Vitamin D-resistenten 
Melanomzelllinie. 
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Danach analysierten wir, inwieweit eine Veränderung der CLU Expression die 
Apoptose-induzierende oder antiproliferative Wirkung von 1,25(OH)2D3 oder 
UV-B auf Zielzellen beeinflußt. 1,25(OH)2D3 wird als mögliches 
Therapeutikum zur Behandlung des malignen Melanoms diskutiert, die UV-B-
Strahlung ist an dessen Pathogenese beteiligt. Zur Untersuchung dieser 
Fragestellung verwendeten wir ein uns zur Verfügung stehendes 
Zellkulturmodell mit humanen LNCaP-Prostatakarzinomzellen die entweder 
sCLU nach stabiler Transfektion vermehrt exprimieren  (LNT-1), oder die nach 
Transfektion des Vektors keine Veränderungen in der Expression von sCLU 
aufweisen (LN/C). Die Effekte der Behandlung mit 1,25(OH)2D3 in 
unterschiedlicher Dosierung (10-6, 10-7, oder 10-10 M) oder mit UV-B (0, 100, 
oder 500 J/m2) auf die Proliferation von LNT-1- und LN/C-Zellen wurde unter 
Verwendung des sogenannten “colony forming ability assays“ verglichen, die 
Apoptoserate unter Verwendung des sogenannten TUNEL Assays.   
Die vermehrte Expression von sCLU schützte LNCaP Prostatakarzinomzellen 
dosisabhängig sowohl gegen die antiproliferativen als auch gegen die 
proapoptotischen Effekte von 1,25(OH)2D3. Dieser Effekt war bei einer 
Konzentration von 10-7 M 1,25(OH)2D3 am stärksten ausgeprägt (30%ige 
Protektion gegen antiproliferative Wirkung, p< 0.1; ~12%ige Protektion gegen 
proapoptotische Wirkung, p< 0.1). Interessanterweise schützte die vermehrte 
Expression von sCLU gegen proapoptotische (~16%, p= 0.038), aber nicht 
gegen antiproliferative Wirkung (~ 0 %) (p> 0.1) der UV-B Bestrahlung. In der 
FACS Analyse zeigten sich in Abhängigkeit von der sCLU Expression in 
LNCaP Zellen weder nach Behandlung mit 1,25(OH)2D3 noch mit UV-B 
Veränderungen in der Zellzyklusregulation. 
 
Die konstitutive CLU Expression, und Veränderungen in deren Expression 
unter Stress können für die Regulation des Tumorwachstums beim malignen 
Melanom und beim Prostatakarzinom von großer Bedeutung sein. Unsere 
Ergebnisse sprechen für eine Bedeutung von CLU für Pathogenese, 
Progression und Therapie dieser Malignome. 
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LIST OF ABBREVIATIONS 
 
1,25(OH)2D3 1,25-dihydroxyvitamin D3 
25(OH)D3 25-hydroxyvitmain D3 
APS amonium persulphate 
ASO antisense oligonucleotide 
BPE bovine pituitary extract 
BSA bovine serum albumin 
CFA colony forming ability assay 
CLU clusterin 
DNA-PK DNA-dependent protein kinase 
DSB double strand break 
EDTA ethelyne-diamine-tetra-acetic acid 
EGFR epidermal growth factor receptor 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
IGF-1R insulin-like growth factor receptor 
IHC immunohistochemistry 
IR ionizing radiation 
IRS immunoreactivity score 
nCLU nuclear clusterin 
NHM normal human melanocytes 
NLS nuclear localization signal 
PEs plating efficiencies 
PMA phorbol myristate acetae 
pnCLU precursor nuclear clusterin 
PP percentage of positive cells 
RXR retinoid X receptor 
sCLU secretory clusterin 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
SI staining intensity 
SiRNA short interfering RNA 
TEMED tetramethylethylenediamine 
TGF-ß transforming growth factor-beta 
TNF-α tumour necrosis factor-alpha 
TUNEL terminal deoxynucleotidyl-mediated dUTP-biotin nick end-labelling 
UV ultraviolet 
VDR vitamin D receptor 
VDREs vitamin D response elements 
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THE SCOPE OF THE STUDY 
 
Human malignant melanoma is a highly aggressive skin cancer, 
compromising only 10% of all skin cancers. Nevertheless, human 
melanocytes are responsible for 85% of skin cancer deaths. Unlike the rest of 
the skin, melanomas are divided from neural crest cells pinched off during 
development. When melanocytes become malignant they invade the 
surrounding healthy skin. Melanoma may stay in the skin, but more often it 
metastasizes through the blood or the lymph system to bones and other 
organs. The standard cytotoxic therapy, dacarbazine, has a response rate 
between 15% and 20% in more optimistic studies and rarely leads to long-
lasting responses. Drug resistance is a major problem for malignant 
melanoma therapy (Namkoong et al., 2006).  
 
Chances are 100%, that if a man lives long enough he will get prostate 
cancer. Prostate cancer kills 1 in 4 men who get the disease, making it one of 
the deadliest forms of cancer. The growth of human cancerous cells in the 
prostate is stimulated by male hormones, especially, testosterone. Prostate 
cancer cells can metastasise to lymph nodes, various bones (especially those 
of the hip and lower back), lungs, and occasionally to the brain. Common 
treatment methods include prostatectomy, chemo- and/or hormonal (e.g., anti-
testosterone) therapies, though drug-resistance occurs more often than not 
(Costello et al., 2006).  
 
It is therefore, extremely important to find new therapies to overcome drug 
resistance for the treatment of human malignant melanoma, as well as human 
prostate cancer. 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3] is a promising agent 
to induce apoptosis in human prostate cancer and melanoma cancers. 
However, due to their hypercalcaemic effects, new vitamin D analogues with 
little or no hypercalcaemic side-effects were introduced. Many of these 
compounds are still under investigation in clinical trials, and the need for a 
new agent in the therapy of human prostate and melanoma cancers is still 
unfulfilled. Secretory clusterin (sCLU), a glycoprotein with antiapoptotic 
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properties, has emerged lately as a target for cancer therapy. Various studies 
showed that silencing sCLU expression led to more efficient therapy outcome.  
We hypothesize that CLU may be related to the pathogenesis and 
progression of certain phenotypes of malignant melanoma, and that CLU has 
a role in UV-B-induced apoptosis. Thus, this study aimed at exploring CLU 
expression in human malignant melanoma cell lines and tissues.  A major 
goal of our study was to test whether CLU expression was modulated by 
1,25(OH)2D3 exposure, and to determine the extent of protection afforded by 
increased sCLU expression in human prostate cancer cell lines following 
various apoptosis-inducing agents. We demonstrated that sCLU is over-
expressed in some of the human melanoma cells used, and expression of this 
gene could be of importance for the pathogenesis and/or progression of 
certain malignant melanoma phenotypes.  
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INTRODUCTION 
 
1.1. PROSTATE CANCER AND MALIGNANT MELANOMA 
Prostate cancer is one of the leading causes of death in men in most western 
countries. The exact causes of prostate cancer are unknown, but both diet 
and genetic inheritance are known to play role in the onset and progression of 
the disease. A hallmark of human prostate cancer cells is their slow growth, 
which can be stimulated by male hormones, especially testosterone. 
Androgen withdrawal, prostatectomy, radiation, and chemotherapy are some 
of the common treatments for prostate cancer (Singh et al., 2006). 
Unfortunately, many of these current anticancer agents are most effective 
against rapidly growing cells, making slow growing prostate cancer cells 
inherently resistant to their effects.  
 
It is accepted that malignant melanoma represents the most dangerous type 
of skin cancer (Millen et al., 2004). UV radiation of normal melanocytes has 
been shown to induce apoptosis and other biologic responses that are 
involved in carcinogenesis (Millen et al., 2004). Therefore and from 
epidemiological studies, ultraviolet (UV) radiation has been discussed as a 
main risk factor in the pathogenesis of malignant melanoma. It is known that 
malignant melanoma has a very low intrinsic level of apoptosis and different 
proteins in the apoptotic pathway can be defective by mutation or loss of 
expression (Hoeller et al. 2005). Treatment of malignant melanoma is difficult 
and varies. According to the stage of its progression, a combination of surgery 
and chemo- or radiotherapy may be needed (Millen et al., 2004).   
 
Due to its anti-proliferative effects, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] 
and its analogues have been used for prostate cancer and melanoma 
treatment. Thus, extensive research was done to find certain agents that 
would increase the efficiency of chemotherapy in these two malignancies.  
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1.2. CLUSTERIN, A HISTORICAL OVERVIEW 
Clusterin (CLU), also known as Apolipoprotein J (Apo J), testosterone-
repressed prostate message-2 (TRPM-2), x-ray-induced transcript leading to 
protein-8 (xip8), sulphated protein 40-40 (SP 40-40), complement lysis 
inhibitor, glycoprotein 80 (gp80), glycoprotein III, tumour protein 64 (T64), or 
sulphate glycoprotein-2 (SG-2), is a secretory heterodimeric disulphide-linked 
glycoprotein (449 amino acids) that is expressed in virtually all tissues and 
found in all human fluids analyzed so far (Trougakos et al., 2002, 2004; Pucci 
et al., 2004; Gleave and Miyake, 2005; Pajak et al., 2006).  It was first isolated 
from rat testes fluid in 1986 by Montpetit et al., and has been implicated in 
various cell functions involved in carcinogenesis and tumour progression, 
including cell adhesion, tissue remodelling, lipid transportation, membrane re-
cycling, immune processes and cell cycle regulation, DNA repair, and in both 
pro- as well as anti-apoptotic cell death processes (Trougakos et al., 2002, 
2004; Pucci et al., 2004). It functions as an extracellular chaperone that 
stabilizes stressed and unfolded proteins in a folding-component state 
(Trougakos et al., 2002). CLU transcription can be regulated by heat shock 
factor-1 and because it binds to a variety of biologic ligands acting to 
potentially inhibit stress-induced protein precipitation, CLU is considered to 
function similarly to a small heat shock protein to chaperone and stabilize 
conformations of proteins at times of cell stress (Gleave et al., 2005).  
Increased CLU mRNA and protein levels have been detected in various 
tissues undergoing stress, including heart, brain, liver, kidney, and retinal 
tissues both in vivo and in vitro. CLU expression was shown to be associated 
with the progression of various human malignancies, including tumours of 
bladder (Miyake et al., 2001), colon (Pucci et al., 2004), prostate (Miyake et 
al., 2000, 2004; Zellweger et al., 2002; Bettuzzi et al., 2002), breast (van 
Weelden et al., 1998; Leskov et al., 2003), lung (July et al., 2004), and kidney 
(Hara et al., 2001). However, the role of CLU in the progression of malignant 
melanoma is yet to be defined. 
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1.3. CLUSTERIN ISOFORMS 
CLU, which is coded by a single gene located on human chromosome 8 
(Pajak et al., 2006), has been attributed two distinct and opposing functions by 
many recent observations, either cell survival, tumour progression, treatment 
resistance in vivo, or apoptosis (Trougakos et al., 2004; Gleave and Miyake, 
2005). In fact, these functions seem to be attributed to the existence of two 
different, but related, CLU protein isoforms, a glycosylated and non-
glycosylated form that are produced in the cell by alternative splicing (Leskov 
et al., 2003). These two forms of the CLU protein can be immunologically 
distinguished (Leskov et al., 2003, reviewed in Shannan et al., 2006, b). 
However, little is known about CLU isoforms in malignant melanoma, and in 
this study we investigated this issue further. 
 
sCLU: The secreted form of the CLU protein (sCLU) is a glycosylated protein 
of ~80 kDa. Depending on the degree of glycosylation, it usually appears as 
two different protein bands by western blot analyses: one full-length non-
cleaved 60 kDa protein, and another rather smeared band appearing as ~40 
kDa α and β proteins as detected by SDS-PAGE (Leskov et al., 2003). The 
expression of sCLU is initiated by the translation from full-length CLU mRNA, 
where the first AUG codon is translated into the 49 kDa sCLU precursor 
protein (Figure 1.2.a) (Leskov et al., 2003; Trougakos et al., 2004, reviewed in 
Shannan et al., 2006 b).  This protein is directed to the endoplasmic reticulum 
by a leader signalling peptide, which is cleaved from the protein during 
transportation. While the protein is being transported towards the golgi, this 
pre-cursor polypeptide is cleaved at its α and β site and subsequently heavily 
glycosylated. The result is a secreted protein of ~80 kDa that consists of α 
and β heavily glycosylated peptides, linked by five disulphide bonds, Figure. 
1.2.b. 
 
nCLU: In contrast, the nuclear form of the CLU protein (nCLU) is an initially 
synthesized 49 kDa protein, referred to as a precursor form of nCLU (i.e. 
pnCLU). In human cells, the pnCLU protein was shown to be synthesized 
from a second in-frame AUG codon from an alternatively spliced nCLU, which 
eliminated exon II that would otherwise encode for the sCLU start AUG and 
    
 
 
16 
signalling leader peptide. It is currently unclear as to how nCLU is expressed 
in rodent cells, since the same splice junction is not conserved. One theory is 
that there is alternative reading from the second AUG start site by intervening 
IRIS sequence-like sequences (Leskov et al., 2003). Interestingly, once made, 
the 49 kDa pnCLU protein does not undergo any α and β cleavage, nor does 
it appear to be heavily glycosylated. pnCLU appears to be localized to the 
cytoplasm of normal human and rodent cells (Figure 1.2.) (Leskov et al., 
2003).  
 
In response to severe cell stress (i.e., exceeding 1 Gray IR), pnCLU is post-
translationally modified and a mature ~55 kDa pro-apoptotic protein form 
(nCLU) is generated and induces apoptosis.  pnCLU is induced and 
translocated from the cytoplasm to the nucleus following certain cytotoxic 
events (Leskov et al., 2003). Despite the fact that the structure/function 
relationship of pnCLU is not completely understood, it appears to contain at 
least two nuclear localization signals that target the nCLU protein to the 
nucleus. Previous studies demonstrated that over-expression of nCLU protein 
with both a C-terminal coiled-coil domain and a functional nuclear localization 
signal (NLSs) only caused cell death. Some experiments have shown a 
mechanism by which the inert pnCLU could be activated to a nCLU ‘death’ 
protein. Recent data indicate that regulation of nCLU into the nuclei of 
irradiated cells occurs through both nuclear localization as well as nuclear 
export sequences. Importantly, mutation of the NLS in the C-terminus of nCLU 
appears to abrogate nCLU functions (Leskov et al., 2003), suggesting that 
nuclear accumulations are essential for the protein’s pro-apoptotic functions.  
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Figure 1.2. Generation of sCLU and nCLU. (a) sCLU precursor is translated from the first 
AUG codon of the full-length CLU mRNA, while nCLU precursor (pnCLU) is obtained by 
alternative splicing from the second in-frame AUG codon of the full-length CLU mRNA. LP: 
leader peptide; NLS: nuclear localization signal. (b) sCLU persursor is transported into the 
rough ER by leader signalling peptide (1), and then undergoes cleavage and extensive 
glycosylation while being transported to the golgi apparatus (2). The result is a secreted 
protein of ~80 kDa with five disulphide bonds between the α- and β-subunit that is secreted 
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outside the cell (3). pnCLU does not undergo any cleavage nor extensive glycosylation, and 
resides in the cytoplasm of unstressed cells. It becomes the mature form (~55 kDa) once it is 
transported to the nucleus. 
 
1.4. IN VIVO FUNCTIONS AND CLUSTERIN 
1.4.1. APOPTOSIS 
Although it has been proposed that CLU up-regulation represents a marker of 
apoptotic response, the precise relationship between CLU gene expression 
and programmed cell death has not yet been elucidated clearly (Yang et al., 
1999). Elucidation of CLU function in cells after stress is clearly complicated 
by the presence of two different forms of the protein that have apparently two 
separate functions in the cell.  
A number of studies have demonstrated that over-expression of the full-length 
CLU mRNA that would produce (depending on where the translation would 
start from and in this case) nCLU that acts as a pro-death signal, inhibiting cell 
growth and survival (Lakins et al., 1998; Jin and Howe, 1999; Trougakos et 
al., 2002).  
However, other studies have shown that CLU over-expression may exert 
cytoprotective properties (Zellweger et al., 2001, 2002, 2003; Miyake et al., 
2002, 2003, 2004; Criswell et al., 2003; Trougakos et al., 2004). Furthermore, 
it has been proposed that tumour cell survival is connected with over-
expression of sCLU and the loss of nCLU (Pucci et al., 2004). This theory has 
been supported by recent data which suggest that cells must suppress sCLU 
to stimulate cell death. One proposed mechanism for this death process is 
through the activation of the p53 tumour suppressor gene (Criswell et al., 
2003). This would explain how progression towards high-grade and metastatic 
carcinoma leads to a shift from nCLU to sCLU expression, and that the role of 
CLU for tumour growth maybe related to a pattern shift in its isoform 
production (Pucci et al., 2004).  
It is well known that the apoptotic pathways are regulated via an orchestrated 
interplay of multiple activators (e.g. tumour necrosis factor, Fas ligand, Bax, 
and p53) and suppressors (e.g. various growth factors and Bcl-2) (Osborne 
and Hutchinson, 2002). In this context, it is interesting that p53, an activator of 
the apoptotic cascade, can suppress basal as well as IR (ionizing radiation)-
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induced sCLU expression in both MCF-7 (breast cancer) and HCT116 (colon 
cancer) cells by repressing CLU promoter activity and transcription (Criswell 
et al., 2003). 
A new report has recently described how CLU may exert an anti-apoptotic or 
pro-apoptotic function by interacting with different proteins depending on its 
distribution. CLU has an essential role in chemoresistance by interacting with 
activated Bax, thereby inhibiting cytochrome C release and apoptosis, and in 
order to induce apoptosis in cancer cells, the CLU-Bax interaction should be 
disturbed (Zhang et al., 2005). It has also been proposed that Ca2+ depletion 
causes pnCLU activation leading it to the nucleus and thus leading to cell 
death (Pajak et al., 2006). In another study, it was also shown that sCLU 
induction is triggered by changes in Ca2+ homeostasis, where a release in 
Ca2+, causes an induction of sCLU (Araki et al., 2005).    
 
1.4.2. CELL CYCLE REGULATION  
The cell cycle is an ordered set of events resulting in cell growth and division 
into two cells. The stages are G1, S, G2, and M. G0 is when cells stop cycling 
after division, entering a state of quiescence. It is still a matter of debate as to 
what extent is CLU expression cell cycle dependent. It was shown that in 
human dermal fibroblasts CLU acts as a cell cycle-related gene, controlled by 
serum starvation, and that CLU protein accumulation occurred in the G0 
phase (Bettuzzi et al., 1999). On the other hand, another study proved that the 
effect of p53 on IR-inducible sCLU expression was not dependent on the cell 
cycle, but was delayed in its induction, requiring at least 48 hrs post IR in 
MCF-7 breast and HCT116 colon cancer cells (Criswell et al., 2003).  
 
The overall function of CLU expression in cell cycle regulation remains 
unclear, and so is the case for CLU expression in UV-induced cell cycle 
changes, which will be discussed in this work. Use of short interfering RNA 
(siRNA) specific to each form of the CLU protein should allow future studies to 
define cause-effect relationships and reveal whether sCLU or nCLU directly 
affect cell cycle regulation with or without cell stress.  
CLU expression was reported to be directly regulated by B-MYB, a 
transcription factor involved in the regulation of cell survival, proliferation, and 
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differentiation (Cervellera et al., 2000). Another transcription factor that was 
reported to be regulated by CLU is NF-κB. Modulation of the NF-κB activity is 
believed of importance for cell survival, cell motility, proliferation, and 
transformation (Sankilli et al., 2003). CLU expression could be required to 
suppress excessive NF-κB activation, which determines inflammation and 
cardiomyocyte apoptosis in autoimmune myocarditis in the rat. Loss of CLU 
expression in cells that depend on NF-κB activity for proliferation or 
chemoresistance could lead to tumour progression (Sankilli et al., 2003).  
 
In a recent study, sCLU expression was shown to be regulated by IGF-1 
receptor (IGF-1R) in MCF-7 breast cancer cells. IGF-1 is secreted by the 
lymph nodes and is thought to be a factor in tumorigenesis of neighbouring 
breast tissues (Criswell et al., 2005). In this study, IGF-1R activation resulted 
in mitogenic growth and cell survival, and a selective inhibitor of IGF-1R 
blocked sCLU induction after IR. The authors stated that the specific 
cytoprotective role of sCLU after IR strongly suggests that activation of IGF-
1/IGF-1R signalling is an essential survival pathway that can be targeted for 
radiotherapy (Criswell et al., 2005). 
 
 
1.5. CLUSTERIN AND DNA REPAIR 
In addition to the function of CLU in mediating apoptosis (Lakins et al., 1998; 
Yang et al., 1999; Trougakos et al., 2002; Criswell et al., 2003; Leskov et al., 
2003), increasing evidence supports an important function for CLU in DNA 
repair (Bettuzzi et al., 1999). Interestingly, CLU has been identified as the first 
stress-inducible protein that is associated with the DNA-dependent protein 
kinases (DNA-PK) double-strand break (DSB) repair complex (Yang et al., 
1999).  
Two types of DSB repair occur after induction of DNA lesions; homologous 
and non-homologous. At least two processes for non-homologous end joining 
of DSBs are thought to occur in mammalian cells, one involving the DNA-PK 
complex, and the other a combination of proteins. nCLU protein binds to 
Ku70, forming a trimeric protein complex with Ku80; Ku70 and Ku80 are two 
components of the DNA-PK complex (Yang et al., 1999, 2000). DNA-PK is a 
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nuclear serine/threonine kinase that requires DNA ends for catalytic activity. It 
is selectively activated by the binding to the ends of linear double-strand 
breaks.  
The exact mechanism by which DNA-PK takes part in physical resealing of a 
DSB is not fully understood. Data showing that over-expression of truncated 
CLU mRNA reduces the binding activity of Ku70/Ku80 to DNA ends in whole-
cell extracts suggests that nCLU may directly affect DSB repair. However, the 
importance of nCLU in DNA repair versus the induction of apoptosis remains 
unclear. Recent data indicate that Ku70 plays an important dual role in binding 
Bax and protecting cells from Bax-mediated cell responses (Suzuki et al., 
2003). Since nCLU and Bax bind Ku70 at the same site (Yang et al., 2000; 
Leskov et al., 2001), it has been proposed that these proteins compete for 
Ku70 binding and that nCLU may free Bax from Ku70. Thus, it is possible that 
nCLU may both free Bax and bind Ku70, thereby inducing apoptosis and 
inhibiting Ku70/Ku80 end binding activity. It is not surprising that a cell 
committing itself to death would perform such functions, since DNA-PK itself is 
a substract for apoptosis-related activated caspase 3 (Mandal et al., 1999). 
Indeed Bax-deficient cells appear to be resistant to nCLU-induced apoptotic 
cell death (Leskov and Boothman et al., unpublished data).    
 
 
1.6. REGULATION OF CLU EXPRESSION IN CANCER CELLS 
A major phenomenological observation is that sCLU levels are altered in 
many cancers at an early stage, however, the exact mechanisms by which 
this gene is permanently up-regulated remains unknown. One hint in the 
process of the gene’s regulation is that a wide variety of different compounds 
involved in the modulation of tumour growth or in cancer therapy can regulate 
CLU expression in both normal and cancer cells. Since vitamin D3 analogues 
(e.g., 1,25-dihydroxyvitamin D3, [1,25(OH)2D3]) have been used to treat some 
tumours, a major goal of my studies was to investigate the role of this agent in 
the up-regulation of sCLU in normal versus tumour cells, and then to explore 
the role of this protein in responses to 1,25(OH)2D3 exposure.    
1,25(OH)2D3 and/or its analogues inhibit proliferation and induce apoptosis in 
a wide variety of cell lines, including cancer cells (James et al., 1996; Narvaez 
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et al., 1996; Simboli-Campbell et al., 1997; Osborne and Hutchinson, 2002; 
Leskov et al., 2003). An increase in sCLU was observed in MCF-7 breast 
cancer cells following 1,25(OH)2D3 treatment as compared to control cells 
(Simboli-Campbell et al., 1996). Increased expression of both sCLU and 
prostatic atrophy markers were observed after treatment of benign prostate 
hyperplasia cells with the 1,25(OH)2D3 analogue, BXL-628 (Crescioli et al., 
2004). BXL-628 inhibited prostate cell proliferation in vivo and in vitro. Since, 
sCLU over-expression in LNCaP cells (some LNCaP clones express very low 
levels of sCLU) may accelerate prostate cancer development through the 
inhibition of membrane damage induced by H2O2 (Miyake et al., 2004).  
 
Other factors that have been shown to affect the expression of CLU in tumour 
cells include various growth factors that mediate proliferation and 
differentiation signals that are important for tumour cell growth. CLU mRNA 
was induced and activated in PC12 prostate cancer cells by nerve growth 
factor and epidermal growth factor (Gutacker et al., 1999). Transforming 
growth factor beta (TGF-β), which is involved in a wide variety of biological 
processes, ranging from embryonic development to neoplastic transformation, 
induces CLU gene expression in various cell types. Transforming growth 
factor beta-1 (TGF-β1), which is a potent inhibitor of the proliferation of many 
cell types and one that is involved in cell cycle control and apoptosis, 
enhanced sCLU protein and mRNA expression in thyroid epithelial cells. Up-
regulation of CLU expression may be a marker for TGF-β1 mediated thyrocyte 
differentiation (Wegrowski et al., 1999). 
 
In rodent cells, CLU gene expression was proposed to occur via a consensus 
AP-1 binding site located in the promoter region of this gene (Jin and Howe, 
1999; Criswell et al., 2003). Further, TGF-β1 induced CLU expression in 
CCL64 mink lung cancer cells was repressed by over-expression of the c-Fos 
proto-oncogene, and it was speculated that TGF-β1 could exert effects on c-
Fos protein synthesis and/or stability, resulting in the repression of c-Fos, and 
thus, increased CLU gene expression. Another important cell survival pathway 
in prostate and other cancers involves IGF-1/IGF-1R signalling pathways that 
converge to block apoptosis. Activated IGF-1R stimulates Ras-Mek-Erk signal 
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transduction to transactivate the early growth response-1 transcription factor, 
which increases sCLU expression (Criswell et al., 2005).  
 
 
1.7. EXPRESSION OF CLU IN MALIGNANT TUMOURS 
1.7.1. ROLE OF CLU AS A PROGNOSTIC MARKER 
Changes in sCLU expression have been documented in a variety of different 
malignancies, including in human prostate, skin, pancreatic, breast, lung, and 
colon tumours, as well as in oesophageal squamous cell carcinoma, and 
neuroblastoma (Trougakos et al., 2004). The primary function of sCLU in 
distinct backgrounds of cancer cells appears to be anti-apoptotic (Trougakos 
et al., 2004).  On the other hand, higher CLU levels were seen in prostate and 
kidney carcinomas when compared with normal tissues. Whether increased 
expression of anti-apoptotic sCLU is a common feature of tumorigenesis, 
thereby protecting cancer cells against apoptotic stimuli that might cause cell 
death, is still a matter of debate. Moreover, the question of whether anti-
apoptotic sCLU is the only form of CLU expressed in cancer, or whether pro-
apoptotic forms of nCLU are down-regulated in distinct tumour entities, has 
not been definitely answered at this time. 
Recent data indicate that progression towards a high-grade and metastatic 
carcinoma leads to elevated sCLU levels and altered intracellular distribution 
of nCLU. Thus, the function of CLU in tumours may be related to a pattern 
shift in its isoform production (Pucci et al., 2004). As discussed above, over-
expression of sCLU was shown in the majority of tumours investigated 
including prostate cancer (Miyake et al., 2003, 2004; Zellweger et al., 2003; 
Scaltriti et al., 2004), breast carcinoma (van Weelden et al., 1998; Redono et 
al., 2002), lung (July et al., 2004), bladder (Miyake et al., 2001), and colon 
(Pucci et al., 2004) cancers. Full-length CLU mRNA and sCLU protein were 
both involved in intestinal tumours (Chen et al., 2003). In prostate cancer, 
sCLU expression was associated with the development of androgen 
resistance and it (i.e., sCLU) is thought to act as a protective factor against 
treatment-induced cell death (Redono et al., 2002; Miyake et al., 2004). A few 
reports, do, however, suggest decreased sCLU levels in specific cancers, 
including nonmelanoma skin cancer (Thomas-Tikhonenko et al., 2004), 
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oesophageal squamous cell carcinoma (Zhang et al., 2003), neuroblastoma 
(Sankilli et al., 2003), prostate (Bettuzzi et al., 2002; Scaltriti et al., 2004), and 
pancreatic cancer (Xie et al., 2002). In addition, in human prostate LNCaP 
cells, CLU appeared to be associated with tumour progression and resistance 
to chemotherapy in vivo (Zellweger et al., 2003). Table 1.7. summarizes the 
expression of sCLU in various tumours.  
In one study, CLU expression was analyzed during progression of prostate 
cancer (Scaltriti et al., 2004). While expression levels of sCLU protein and full-
length CLU mRNA were non-detectable in prostate carcinoma cells, high 
expression levels of CLU protein and mRNA were found in stromal 
peritumoral fibroblasts. In different stages of tumour progression, sCLU 
accumulated in specific, well-defined areas of the stromal compartments near 
these tumours.  
In advanced prostate cancer, staining of remnants of the extracellular matrix 
suggested a role for sCLU in the process of dismantling the stromal 
organization caused by prostate cancer (Scaltriti et al., 2004). CLU expression 
was induced in pancreatic cancer and its down-regulation may be associated 
with disease progression (Xie et al., 2004). It is not clear, however, in these 
studies if sCLU versus nCLU expression levels were clearly separable. There 
is a need for improved methods to detect nCLU in cases like this. Thus, 
although the majority of studies indicate that sCLU expression is up-regulated 
along with the progression of distinct malignancies, its role as a prognostic 
factor is still questionable and more research examining expression levels of 
sCLU versus nCLU in these cancers is needed (Miyake et al., 2000, 2001, 
2004; Chen et al., 2003; Zellweger et al., 2003; Pucci et al., 2004).  
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Table 1.7. Summary of CLU expression in various tumours as observed by 
various studies 
Tumour CLU expression  Reference 
Prostate cancer *↑ mRNA and protein Lakins, 1998; Miyake 2002; 
Zellweger, 2002, 2003 
Breast carcinoma ↑ mRNA Van Weelden 1998; 
Leskov, 2003 
Lung cancer ↑ mRNA July, 2004 
Colon cancer ↑ mRNA and protein Seiberg, 1995; Pucci, 2004 
Skin cancer **↓ mRNA Redono, 2002 
Oesophageal squamous 
cell carcinoma 
↓ Protein Chen, 2003 
Neuroblastoma cancers ↓ Protein Thomas-Tikhonenko, 2004 
Pancreatic cancer ↓ mRNA Zhang, 2003 
Prostate cancer ↓ mRNA Bettuzzi, 2002; Scaltriti, 
2004 
*↑: increase in expression; **↓: decrease in expression 
   
 
In contrast to prostate and pancreatic cancers, sCLU levels have been 
implicated as having prognostic value in specific cancers, such as colon and 
breast. sCLU was reported to be a prognostic indicator in tumorigenesis and 
progression of human breast carcinoma (Redono et al., 2002). Furthermore, 
sCLU has been proposed to be a potentially new prognostic and predictive 
marker for colon carcinoma aggressiveness, since over-expression of sCLU is 
reported or observed in highly aggressive tumours as well as metastatic 
nodules (Pucci et al., 2004). Thus, as with overall basal levels of sCLU, the 
notion of whether changes in sCLU expression may be an indicator of 
treatment response is still to be elucidated.  
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1.7.2. ROLE OF sCLU AS A DIAGNOSTIC MARKER 
The sCLU antigen has been characterized as a sensitive and stable 
histological marker for murine and human intestinal tumours, where elevated 
levels of sCLU were found in normal human colon crypts adjacent to 
adenomas or adenocarcinomas, but not in normal crypts far removed from the 
tumours or tumour-free crypts (Chen et al., 2003). This property may indicate 
that sCLU is a potential biomarker for diagnosis of human colorectal cancer 
using immunohistochemical or molecular biology techniques. Furthermore, the 
elevated production of sCLU antigen, if secreted from tumour cells, as 
proposed by the authors, may be detected in body fluids, such as serum 
(Chen et al., 2003). Consequently, it was speculated that markers derived 
from sCLU may be used as part of a set of indices for early detection of 
human colorectal cancer (Chen et al., 2003). sCLU was identified as a marker 
of anaplastic large-cell lymphoma (Saffer et al., 2002) and it has been 
recommended that sCLU should be added as a useful biomarker to antibody 
panels designed to distinguish systemic anaplastic cell lymphoma from 
classical Hodgkin’s lymphoma (Saffer et al., 2002). Thus, an increasing body 
of evidence now indicates that the specific expression patterns of sCLU and 
its correlation with cellular events during tumorigensis make it a promising 
diagnostic tool in anaplastic cell large-cell lymphoma, as well as in other 
malignancies. Hence, sCLU is a potential contributor to the set of biomarkers 
for early detection of a variety of cancers, especially for colon cancer.  
 
 
1.8. CLUSTERIN AS A THERAPEUTIC TARGET 
1.8.1. ANTISENSE OLIGONUCLEOTIDES 
Recent scientific findings demonstrate that drugs targeting sCLU expression, 
including CLU silencing using antisense oligonucleotides (ASO) or short 
interfering RNA (siRNA), may become promising tools for cancer therapy 
(Zellweger et al., 2001; Criswell et al., 2003; Gleave and Miyake, 2005). It is 
now accepted that the primary function of the 76-80 kDa sCLU protein form is 
cytoprotective. Resistance to cancer treatment is mediated, at least in part, by 
enhanced expression of cell survival proteins that help facilitate tumour 
progression (Miyake et al., 2000). Thus, it has become increasingly clear that 
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in most cells, sCLU is a stress-associated cytoprotective protein that is up-
regulated by various apoptotic triggers. Furthermore, sCLU confers resistance 
by some unknown mechanism when over-expressed (Miyake et al., 2000). 
The novel therapeutic strategy of silencing sCLU expression to overcome 
resistance to cancer therapy is of interest for the treatment of cancers that 
over-express sCLU (reviewed in Gleave and Monia, 2005). 
 
It has been hypothesized that sCLU over-expression may influence the 
apoptotic response of prostate tumour cells to IR and that the up-regulation of 
CLU after various apoptotic signals represents an adaptive cell survival 
mechanism, thereby affecting a potential target for down-regulation to improve 
the results of radiation therapy for patients with prostate cancer (Zellweger et 
al., 2003). Thus, sCLU over-expression helps to confer a chemoresistant 
phenotype through inhibition of apoptosis in human renal cell carcinoma cells 
(Hara et al., 2001). Furthermore, sCLU was supported as a valid therapeutic 
target in strategies employing novel multimodality therapy for advanced 
prostate cancer, as sCLU is up-regulated following androgen withdrawal 
therapy, and this may represent an adaptive cell survival response following 
apoptotic signals like androgen withdrawal (July et al., 2002).  
 
1.8.2. SHORT INTERFERING RNA 
It has been hypothesized that sCLU gene silencing using siRNA or other 
techniques may ultimately develop into attractive anti-tumour therapeutics 
(Trougakos et al., 2004). It has recently been shown that sCLU knockdown in 
human cancer cells, using siRNA-mediated CLU gene silencing, induces 
significant reduction of cellular growth and higher rates of spontaneous 
apoptosis (Trougakos et al., 2004). sCLU provides cytoprotection for IR-
exposed MCF-7 breast cancer cells that is not observed after siRNA to silence 
CLU gene (Criswell et al., 2003). The most common delivery method of siRNA 
for in vitro application is the use of cationic lipids. This system provides 
reasonable transfection efficiencies in cell culture in vitro, as these cationic 
lipids are too toxic in vivo. Thus, the use of cationic polymers (mainly 
polyethylenimine, PEI) grafted with polyethylene glycol (PEG), which reduces 
the toxicity of the cationic polymers, was introduced (Sutton et al., 2006). 
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Thus, PEG-grafted PEI was shown to bind to siRNA and form nanometer-
sized complexes. These nanocomplexes inhibited sCLU expression as well as 
its IR-induced up-regulation in MCF-7 cells, resulting in increased IR lethality. 
These results validate the concept of using polymer delivered siRNA to 
specifically down-regulate sCLU as an aid to cancer radiotherapy (Sutton et 
al., 2006).   
 
However, great care in reducing sCLU levels without affecting nCLU levels 
must be taken using siRNA targeted against a specific CLU isoform. siRNA 
knockdown CLU levels enhances cytotoxic agent efficiency, whereas siRNA 
specific to sCLU enhances the efficacy of cytotoxic agents, whereas siRNA 
against nCLU confers cytoprotection against a variety of chemotherapeutics.        
 
 
1.9. 1,25-DIHYDROXYVITAMIN D3 
1.9.1. BACKGROUND 
Vitamin D is a generic designation for a group of fat-soluble, structurally 
similar sterols, several of which are important in calcium and phosphorus 
metabolism, and bone formation. The two most important sterols are vitamin 
D2 (ergosterol), and vitamin D3 (calcitriol). Vitamin D3 is found in certain 
animal tissues and products. It is also synthesised in the skin by ultraviolet 
(UV) irradiation of 7-dehydrocholesterol. Vitamin D3 is transported to the liver, 
where it undergoes hydroxylation to produce 25-hydroxyvitamin D3 
(25(OH)D3). Although 25(OH)D3 has limited biological activity, it is the major 
circulating metabolite of vitamin D3. In the kidney, 25(OH)D3 undergoes 
further hydroxylation to form dihydroxy metabolites: 1,25(OH)2D3, 
23,25(OH)2D3, and 24,25(OH)2D3. The 23-metabolite is biologically inert and 
its function is still unknown. The production of 1,25(OH)2D3, the active 
metabolite of vitamin D3, is regulated by a negative feedback mechanism 
depending on the need for calcium and phosphorus in circulation (Holick, 
2003) (Figure 1.9). 
1,25(OH)2D3 has also been shown to have significant anti-proliferative activity 
when administered to many cancer cells in vitro. 1,25(OH)2D3 regulates 
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growth and differentiation in various cell types (Hansen et al., 2001; Seifert et 
al., 2004). 1,25(OH)2D3 acts by binding to a corresponding intra-nuclear
 
receptor (VDR), present in target tissues (Stumpf et al., 1979; Baker et al., 
1988). VDR belongs to a superfamily of trans-acting transcriptional regulatory 
factors that includes steroid and thyroid hormone receptors as well as retinoic 
acid and retinoic-X (RXR) receptors (Kliewer et al., 1992; Evans et al., 1988).  
VDR functions as a ligand-activated transcription factor that binds to vitamin 
D-responsive elements (VDREs) in the promoter regions of vitamin D-
responsive genes (Bao et al., 2004). VDR binds with high affinity to VDREs by 
forming a heterodimeric complex with the RXR. The VDR/RXR heterodimers 
function as transcriptional factors in regulating vitamin D-mediated gene 
expression (Bao et al., 2004). The effects of VDR-mediated genomic 
pathways include inhibition of cellular growth and invasion. Non-genomic 
cytoplasmic signalling pathways are increasingly being recognized, which 
similarly may regulate not only cellular growth and differentiation but also 
apoptosis.  
1,25(OH)2D3 can exert a significant inhibitory effect on the G1/S checkpoint of 
the cell cycle and may produce complete arrest by up-regulating the cyclin 
dependent kinase inhibitors, p27 and p21. 1,25(OH)2D3 can also inhibit cyclin 
D1 (Osborne and Hutchinson, 2002). Indirect mechanisms of 1,25(OH)2D3-
mediated growth regulation include up-regulation of TGF-ß1 and down-
regulation of the epidermal growth factor receptor (EGFR) (Osborne and 
Hutchinson, 2002). 1,25(OH)2D3 has the capacity to induce apoptosis either 
indirectly through effects on the insulin-like growth factor receptor (IGF-1R) 
and tumour necrosis factor-α (TNF- α) or more directly via the Bcl-2 family 
system, the ceramide pathway, the death receptors (e.g. Fas) and the stress-
activated protein kinase pathways (i.e., Jun N terminal kinase and p38) 
(Danielsson et al., 1998; Osborne and Hutchinson, 2002).  
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(b) 
 
 
Figure 9.1.1. 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). (a) 1,25(OH)2D3 is obtained either from 
the diet or from skin exposure to UV-B. The compound is then transported to the liver and 
undergoes hydroxylation to produce 25-hydroxyvitamin D3. In the kidney, 25-hydroxyvitamin 
D3 undergoes further hydroxylation to produced dihydroxy metabolites, and one of them is 
1,25-dihydroxyvitamin D3, the active metabolite. (b) The chemical structure of 1,25(OH)2D3.   
 
1.9.2. ROLE OF VITAMIN D3 IN MALIGNANCIES 
The 1,25(OH)2D3-mediated effects on cell death, tumour invasion and 
angiogenesis make vitamin D analogues promising candidate agents for 
cancer therapy (Osborne and Hutchinson, 2002). 1,25(OH)2D3 and its 
analogues inhibit proliferation and induce differentiation and apoptosis in 
various malignancies, including human malignant melanoma, and prostate 
cancer (Danielsson et al., 1998; Hansen et al., 2001; Seifert et al., 2004).  
Unfortunately resistance to vitamin D analogue treatment remains a serious 
problem. Tumour cell lines that fail to respond to the anti-proliferative effects 
of vitamin D analogues have also been reported. Vitamin D-induced apoptosis 
was demonstrated in melanoma cell lines (Danielsson et al., 1998). Inhibition 
of tumour invasion and metastasis by 1,25(OH)2D3 has been demonstrated as 
OH 
25 
1 
OH 
OH 
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well, and the mechanisms involved include inhibition of serine proteinases, 
metallo-proteinases and angiogenesis (Osborne and Hutchinson, 2002; 
Seifert et al., 2004). Vitamin D analogues exposure can reduce autocrine 
TGF-ß1 activity by increasing expression of TGF-ß isoforms and/or TGF-ß 
receptors in non-malignant and malignant breast cells. Further, Smad 3, a 
TGF-ß1 signalling mediator, co-activates VDR to further enhance TGF-ß and 
vitamin D signalling (Masuda and Jones, 2006).  
In several prostate cancer models, 1,25(OH)2D3 can induce apoptosis, and 
this often involves down-regulating the anti-apoptotic protein, Bcl-2. Reduced 
expression of Akt, a kinase that regulates an important survival pathway that 
involves down-regulation of p53 (Mayo et al., 2005) may also contribute to the 
pro-apoptotic activity of 1,25(OH)2D3. p53 is thought to be involved in 
1,25(OH)2D3-induced apoptosis, however, there is conflicting information 
about its role in this 1,25(OH)2D3-induced apoptosis.  
One role for vitamin D analogues could be in their use as synergistic agents 
for the treatment of cancer. 1,25(OH)2D3 has been shown to produce additive 
or synergistic activities when combined with several classes if anti-neoplastic 
agents that are relevant for the treatment of human prostate cancer (Beer et 
al., 2005).  
In malignant melanoma, 1,25(OH)2D3 or its analogues represent a palliative 
therapy for the metastasis of malignant melanoma. However, as mentioned 
above, it has been shown that certain melanoma cell lines fail to respond to 
the anti-proliferative effects of vitamin D analogues. The reason is thought to 
be due to a defect in VDR-mediated transcription (Seifert et al., 2004), but 
more research in this area is warranted. Since CLU has important functions in 
apoptosis, it is essential to examine a possible relation between 1,25(OH)2D3 
and CLU signalling pathways. 
This research was focused on examining any differences in CLU expression 
in malignant melanoma cells, both untreated and 1,25(OH)2D3 treated. The 
results from this work would bring further understanding to the progression 
and pathogenesis of malignant melanoma. 
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 2.   MATERIALS AND METHODS 
 
2.1. DETECTION OF CLU IN VIVO 
2.1.1. TISSUES 
We analyzed immunohistochemically paraffin sections of primary cutaneous 
malignant melanomas (n= 18), metastases of malignant melanomas (n= 25) 
and acquired melanocytic nevi (n= 30). Other tissues (basal cell carcinoma n= 
5, Merkel’s cell carcinoma n= 5, and cutaneous squamous cell carcinoma n= 
5) were also tested. Table 2.1. summarizes the histological data of the tissues 
analyzed. The tissues were obtained from the Saarland University Hospital, 
Dermatology Department, 66421 Homburg/Saar. The diagnoses of the cases 
were made by certified histopathologists in the Dermatology Department.  
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2.1.2. IMMUNOHISTOCHEMISTRY 
The tissues were fixed in 4% formalin overnight and cut into 5 mm sections 
using a Reichert-Jung 2030 microtome (Heidelberg, Germany). After the 
tissue sections were attached to slides and dried, they were deparafinized in 
xylene and hydrated using graded alcohols and finally washed in distilled 
water. The tissues were then incubated in PBS and analyzed using Clusterin-
α/ß (H-330) antibody for 1 hr at room temperature (rabbit polyclonal, working 
dilution 1:100, Santa Cruz, CA, USA) and a streptavidin-peroxidase 
technique. The primary antibody detects both CLU isoforms (Dr. Gleave, 
University of British Colombia, Vancouver General Hospital, Canada, personal 
communication). Primary antibody binding was detected by a two-step 
biotin/streptavidin based antibody detection system employing a peroxidase-
mediated 3-Amino-9-Ethylcarbazol staining (Sigma Immunodiagnostics, 
Taufkirchen, Germany). Incubation with 2% peroxidase in methanol was used 
to block endogenous peroxidase activity. The tissues were mounted in 
permanent Aquatex media (MERCK Biosciences, Schwalbach/Ts., Germany). 
Immunohistochemical staining was evaluated semi-quantitatively, estimating 
staining intensity (SI: 0= no staining, 1= low staining, 2= moderate staining, 3= 
strong staining) and percentage of positive cells (PP: 0= no positive cells, 1= 
1-50% positive cells, 2= 51<75% positive cells, 3= > 75% positive cells) and 
calculating a resulting immunoreactivity score (IRS = SI x PP). Semi-
quantitative analyses were performed by two independent observers (B.S. 
and J. R.) (Shannan et al., 2006, a).   
 
 
2.2. DETECTION OF CLU IN VITRO 
2.2.1. CELL CULTURE 
Human melanoma cell lines SK-MEL-28, SK-MEL-5, SK-MEL-25 (23), and 
MeWo (24), were cultivated in RPMI 1640 media (10% foetal calf serum 
[FCS], 37°C, 5% CO2) (PAA Laboratories GmbH, Coelber, Germany) using 
10-cm plates (Greiner Bio-One GmbH, Frickenhausen, Germany) or 6-well 
plates (Greiner). Melanoma cell lines were previously characterized as vitamin 
D-resistant and -sensitive (Seifert et al., 2004). Vitamin D-resistant melanoma 
cell lines are thought to have a functional defect in VDR-mediated gene 
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transcription. Primary normal human melanocytes (NHM) were isolated from 
human foreskin and cultivated in serum free melanocyte growth media 
(PromoCell, Heidelberg, Germany), after addition of supplement mix (10 
ng/ml PMA, 0.5 µg/ml Insulin, 0.5 µg/ml hydrocortisone, 2 ml BPE, and 1.0 
ng/ml gentamycin/amphotericin B). Human LNCaP prostate cells that were 
trasfected with a control vector alone (LN/C) and stable transfected sCLU 
over-expressing prostate cells (LNT-1) (Zellweger et al., 2003) were cultivated 
in RPMI 1640 medium (5% FCS, 300 µg/ml G-418 to maintain stable 
transfected sCLU over-expression, 37°C, 5% CO2) (PAA) using 10-cm plates 
(Greiner). The LNCaP cells were kindly provided by Dr. David Boothman 
(University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 
USA). Around 50% confluent cells were incubated with 1% bovine serum 
albumin [BSA] dissolved in RPMI 1640 medium and treated with 1,25(OH)2D3 
(10-10 M, 10-7 M, or 10-6 M). Various experiments were then performed on the 
cell lines (PCR, RT-PCR, colony forming assay, cell cycle analysis, and 
TUNEL). An ethanol (vehicle) control was used due to the fact that 
1,25(OH)2D3 is water-insoluble and is dissolved in ethanol. 1,25(OH)2D3 was 
kindly provided by Dr. Lise Binderup (Leo Pharmaceuticals, Ballerup, 
Denmark). 
 
 
2.2.2. ULTRAVIOLET-B IRRADIATION 
Human LNCaP prostate cells were irradiated with UV-B to evaluate the 
differences between LNT-1 and LN/C. The ultraviolet-B (UV-B) irradiation 
source was a fluorescent lamp that emitted an energy peak at 306 nm 
(Waldmann, Villingen-Schwenningen, Germany). The emitted dose was 
calculated using a UV-B radiometer photodetector.  Cells were plated on 10-
cm plates (Greiner) and left overnight to attach. The cells were then washed 
once with phosphate buffered saline (PBS) before being irradiated using UV-B 
lamp. The UV-B doses were as follows: 0, 100, and 500 J/m2 for colony 
forming ability assays, cell cycle analyses, and TUNEL analyses. Only LNCaP 
prostate cells were irradiated with UV-B to test for the difference between the 
sCLU transfected (LNT-1) and the empty vector transfected (LN/C) cell lines.  
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2.2.3. RNA ANALYSES 
2.2.3.1 RNA EXTRACTION 
Cells were harvested and total RNA was isolated using RNAeasy MiniKit 
(QIAGEN®, Hilden, Germany) according to the manufacturer’s 
recommendations. The integrity and amount of extracted total RNA were 
monitored by gel electrophoresis and spectrophotometric analyses. The 
integrity of RNA was checked by mixing 1µl of the isolated RNA, 3µl of gel 
loading solution (Sigma-Aldrich, Taufkirchen, Germany), and 9µl distilled 
water. The mixture was applied to a 2% agarose gel (run at 70 Volt for 1hr). 
Bands were then visualized using a Biometra TI 2 transilluminator (230 Volt). 
The amount of RNA was checked by measuring (260-280λ) the isolated RNA 
(1:50 dilution) using a spectrophotometer (Ultraspec 1000, Pharmacia 
Biotech, Germany) 
 
2.2.3.2. RNA REVERSE TRANSCRIPTION 
RNA was reverse-transcribed into cDNA either with a method using 
Omniscript reverse transcription (QIAGEN®), or using M-MLV RT H(-) point 
with poly-dT-primer (Promega GmbH, Mannheim, Germany). The existence of 
genomic DNA contamination was excluded via reverse transcriptase-minus 
reaction.  
 
2.2.3.3. POLYMERASE CHAIN REACTION 
The polymerase chain reaction (PCR) protocols were established with specific 
oligonucleotide primers for CLU, which is a low expressed gene (primer 
synthesis by TIB MOLBIOL, Berlin, Germany), and ß2-microglobulin (ß2-
µglob, housekeeping gene; TIB MOLBIOL); in separate approaches: 2 µl 
cDNA were added to a master mix containing 1.5 mM MgCl2, 4 nM dNTP, 10 
pmol of each specific oligonucleotide (ß2-µglob), 10 pmol (CLU), 5 U Taq 
polymerase (Eppendorf, Hamburg, Germany) and 1 x Taq buffer advanced 
(Eppendorf) in a total volume of 50 µl. The primer sequences for ß2-µglob and 
CLU are shown in Table 2.2.3.3.  
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Semi-quantitative mRNA expression analysis of different cell lines was based 
on consecutively performed co-amplifications of CLU with ß2-µglob mRNA 
isolates. To co-amplify CLU and ß2-µglob transcripts, 35 and 20 PCR cycles 
were performed, respectively, with the conditions listed in Table 2.4.3. PCR 
products were separated on 2.5% agarose gels containing 1 µg/ml ethidium 
bromide and visualized by UV-light at 366 nm. A step ladder 50bp marker was 
run with the samples (Sigma). The gel image was documented and processed 
using a digital documentation system (Gel Print, 2000i, MWG-Biotech, 
Ebersberg, Germany).  
Semi-quantitative analysis were performed using optical densitometry and 
NIH Image J, a public domain Java image processing programme that was 
used to create density histograms and line profile plots. All PCR runs were 
performed in duplicates and experiments were repeated at least twice. To 
enable us to obtain quantitative results, we developed a real-time RT-PCR 
technique, as indicated, for the detection of CLU in human melanoma cell 
lines. 
 
 
Table 2.2.3.3. PCR primer sequences and amplification conditions 
Primer Sequence 
CLUSex6 F (Exon 6) 5΄-AAACCTCACgCAAggCgAA-3΄ 
CLUSex7 A (Exon 7) 5΄-CCgCCACggTCTCCATAA-3΄ 
ß2-µglob se 5΄-CCAgCAgAgAATggAAAgTC-3΄ 
ß2-µglob as 5΄-gATgCTgCTTACATgTCTCg-3΄ 
Protocol: 35 (CLU) and 20 (ß2-µglob) cycles: 94°C for 1 min, 94°C for  20 
secs, 55°C for 30 secs, 72°C for 30 secs, 72°C for 7 min, 4°C cool. 
 
2.2.3.4. Real-time RT-PCR 
Two microliters each of a 1:5 dilution of RT reaction mixture were used as the 
template for real-time PCR, containing 5 and 4 mmol/L Mg Cl2 for CLU gene 
and β2 microglobulin (β2-µglob) respectively; and 0.5 mmol/L primers as 
shown in Table 2.2.3.4. After adding 10 µl mix from the SYBER Green I kit 
(Qiagen), the volume was adjusted to 20 µl with nuclease-free distilled water.  
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Table 2.2.3.4. Real-time RT-PCR primer sequences and amplification 
conditions 
Primer Sequence 
ß2-µglob se 5	- CCA gCA gAg AAT ggA AAg TC -
3 
ß2-µglob as 5	- gAT gCT gCT TAC ATg TCT Cg   -
3 
Hs_CLU_1_S
G 
Purchased from Qiagen QuantiTech, Catalogue number 
QT00054460 
Protocol: 95°C for 15 min, 60 cycles:  95°C for 20 secs, 55°C for 20 secs, 
72°C for 20 secs. Melting curve: 65°C for 15 secs, 95°C, cool. 
 
The samples were amplified in the LightCycler System and PCR was 
performed by an initial amplification step at 95ºC for 15 min followed by 60 
cycles with a denaturation step at 95ºC for 20 secs, primer annealing at 55ºC 
for 20 secs, and an extension phase at 72ºC for 20 secs. A melting curve was 
generated after 60 cycles for the final PCR product for all genes investigated 
by decreasing the temperature to 65ºC for 15 secs followed by a slow 
increase in the temperature to 95ºC. During the slow heating process the 
fluorescence was measured at 0.2ºC increments. To further insure specificity, 
gel electrophoresis was conducted for selected samples of each specific 
product. In all cases bands of the expected size were consistently observed.  
Construction of a standard curve for CLU was achieved using cDNA from 
cultured prostate LNCaP cells (LNT-1) that over-express CLU (as mentioned 
in section 2.3.). Total RNA was prepared from 1 x 106 LNT-1 cells and used 
for cDNA synthesis. Five 10-fold serial dilutions of the retrieved cDNA were 
used as external standards to determine PCR efficiency. The same was 
performed to achieve a standard curve for β2-µglob, used as a housekeeping 
control gene, only the cDNA was obtained from a cultured melanoma cell line, 
MeWo.  
To generate a calibrator for CLU, RNA from LNT-1 cells was used for cDNA 
synthesis in several reaction tubes. The reaction mixture was diluted 1:10 and 
kept in aliquots at -20ºC. Two microliters each were used per LightCycler run.  
The relative amount of target gene mRNA (CLU) and of reference gene (β2-
µglob) was determined for each sample and the calibrator (LNT-1), integrated 
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into each LightCycler run. The relative ratio of target to reference for each 
sample and for the calibrator was calculated first. This corrects for sample-to-
sample variations caused by differences in initial quality and quantity of the 
nucleic acid-the basic concept of each relative quantification (Roche, technical 
note LC 13/2001). The target/reference ratio of each sample was finally 
divided by the target/reference ratio of the calibrator. The calculation of the 
relative amount of any target or reference gene is based on the crossing point 
of the PCR reaction. PCR efficiency is expressed as E = 10-1/slope.  
 
The calculations of normalized ratio are made according to the following 
formula: 
 
Normalized ratio = ET
CpT(C)-CpT(S) x ER
CpR(S)-CpR(C) 
  
Where E = efficiency, T = target, R = reference, S = unknown sample, C = 
calibrator, and Cp = crossing point.  
 
This procedure was used to compensate for different detection sensitivities of 
target and reference amplifications, providing a constant calibrator point 
between PCR runs. 
 
 
2.2.4. WESTERN BLOT ANALYSES 
After 1,25(OH)2D3 or UV-B treatment, the cells (melanoma and LNCaP 
prostate cell lines) were harvested and protein was isolated using a double 
volume of the pellet in RIPA buffer, and complete EDTA (ethelyne-diamine-
tetra-acetic acid) free protease-inhibitor-cocktail tablets (Roche Diagnostics). 
The proteins were then detected by western blot analyses using a CLU 
specific primary mouse monoclonal antibody (clone 41D, Upstate, Hamburg, 
Germany) with a working dilution of 1:1000. The samples included equal 
volumes of protein (150 µg) and were separated on an SDS-PAGE gel using 
electrophoresis buffer. The SDS-PAGE gel was run for 1.5 hrs at 65 mAmp, 
and consisted of a separation gel (12.5%) and a collection gel (5%). A 
prestained protein molecular weight marker was run with the samples 
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(Fermentas, St. Leon-Rot, Germany). The protein samples were then 
transfected to nitrocellulose membranes using transfection buffer in a buffer 
tank for 16 hrs at 45 mAmp. The membranes were blocked in TBS containing 
5% nonfat milk powder for 1 hr at room temperature. The primary antibody 
was added to the membranes (1 hr, room temperature). After a washing step, 
the secondary antibody labelled with peroxides (goat anti-mouse, Sigma 
Immunodiagnostics, 1:30000 working dilution) was added. A horseradish 
peroxidase-based detection reagent was added for 5 minutes (Amersham 
Biosciences, Buckinghamshire, UK). The membranes were then washed 
several times using TBS. The immunoblots were detected afterwards by 
chemoluminescence according to the manufacturer’s instructions (Roche 
Molecular Biochemicals) using Lumi-films chemiluminescent detection films 
(Roche). The membranes were then stripped using the following stripping 
buffer, and actin antibody (goat polyclonal IgG, working dilution 1:500, Santa 
Cruz) was used as a loading control. The buffers and solutions used in the 
western blot analyses are summarized in Table 2.2.4. 
 
Table 2.2.4. The buffers and solutions used in the western blot analyses 
Collection Gel (5%) 0.375 mL Solution A, 0.8 mL Solution C, 2.125 mL distilled 
water, 2.7 µl TEMED, 33.3 µl APS (10%) 
Electrophoresis buffer 0.025 M Tris-HCl/ pH 8.3, 0.132 M glycine, 0.1% SDS 
RIPA Buffer (extraction 
buffer) 
50 mM Tris-HCl/ pH 8.0, 150 mM NaCl, 0.5% sodium 
deoxycholate, 0.1% SDS, 1% Triton X 100 
Separation Gel (12.5%) 3.15 mL Solution A, 2.5 mL Solution B, 4.35 mL distilled water, 
8.3 µl TEMED, 100 µl APS (10%)  
Solution A 40% Acrylamid, 1.04% Bis-acrylamid 
Solution B 1.5 M Tris-HCl/ pH 8.8, 0.4% SDS 
Solution C 0.5 M Tris-HCl/ pH 6.8, 0.4% SDS 
Stripping Buffer 25 mM glycine, 2% SDS, pH 1.0 
TBS 10 mM Tris-HCl/ pH 8.0, 150 mM NaCl with 0.05% Tween 20 
Transfection Buffer 20 mM Tris-HCl/ pH 8.3, 150 mM glycine 
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2.2.5. CELL VIABILITY ASSAYS 
2.2.5.1. COLONY FORMING ASSAY (CFA) 
MeWo, SK-MEL-25 and LNCaP cells were seeded in 10-cm plates with 
10,000 cells/plate (for melanoma cells) and 15,000 cells/plate (for LNCaP 
cells). The number of cells was determined following a separate CFA 
assessing the platting efficiency of these cells. After 24 hrs, cells were treated 
with 1,25(OH)2D3 (10
-6, 10-7, or 10-10 M), and cultured in BSA medium for 7 
days continually. Fresh medium and treatment were given daily. Then the 
cells were fixed in ethanol and stained using crystal violet dye. Finally, the 
sum of colonies was counted and the inhibitory rate of colony-forming 
(proliferation) following treatment with 1,25(OH)2D3 was calculated. 
Experiments were performed in duplicate and repeated at least twice. 
 
2.2.5.2. CELL CYCLE ANALYSES 
LNCaP cells were seeded into 10-cm plates, left to attach overnight and 
treated the next day with 1,25(OH)2D3 or UV-B. Following various time points, 
cells were harvested and fixed in 70% methanol in PBS at RT for 30 min. 
Cells were then pelleted and resuspended in 1 mL PBS. 100 µL of 1 mg/mL 
RNase A (DNase-free) and 100 µL of propidium iodide were added. The cells 
were incubated at 37°C for 30 min. Cell cycle analysis was then measured 
using the FACscan flow cytometry, as described below (section 2.2.6.). 
Experiments were performed in duplicates and repeated at least twice.  
 
2.2.5.3. TUNEL ASSAY 
Detection of DNA fragmentation  in situ in LNCaP cells following 1,25(OH)2D3 
treatment was detected by TUNEL (terminal deoxynucleotidyl-mediated 
dUTP-biotin nick end-labelling) assays using the Cell Death Detection Kit 
(Roche Diagnostics®, Mannheim, Germany). This assay relies on fluorescent 
in situ labelling of DNA strand breaks. An equal number of cells was seeded in 
duplicate on 10-cm plates, allowed to attach overnight, and treated with BSA 
medium and 1,25(OH)2D3 daily. After 72 hrs of treatment, cells were 
harvested and cell density adjusted to 2x105, and DNA fragmentation was 
detected by TUNEL according to the manufacturer’s instructions. Apoptosis 
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was measured using the FACscan flow cytometry (Beckman Coulter, Krefeld, 
Germany). Experiments were repeated three times each in duplicate.    
 
 
2.2.6. FLOW CYTOMETRIC ANALYSES (FACS) 
Flow cytometric analyses were performed using fluorescence activated cell 
sorting (FACS) device. It is a method for quantifying components or structural 
features of cells primarily by optical means. Although it is limited to 
measurements on single-cell basis, it can process thousands of cells in a few 
seconds. Laser-based flow cytometry includes a cell transporter system, a 
laser light source, a flow chamber, mono-chromatic filters, lenses, dictoric 
mirrors, photomultiplier tubes, and a computer for data analysis. The cell 
suspension, to be analyzed, is introduced into the flow chamber by air 
pressure. As cells pass through the flow chamber, they are surrounded by a 
low-pressure sheath fluid. The outer fluid stream creates a laminar flow 
forcing the specimen to the centre, and results in a single-file alignment of 
individual cells. This process is known as hydrodynamic focusing. Every cell 
sample is then intersected by a laser beam. Each cell scatters some of the 
laser light, and also emits fluorescent light excited by the laser. The forward 
light scatter is proportional to the cell size and the 90º or right angle scatter is 
related to the cell granuality and density. These two scatters build a specific 
programme for each assay/cell line (Henry, 1996). The cells were prepared as 
mentioned in sections 2.2.5.2. and 2.2.5.3. 
 
2.2.7. STATISTICAL ANALYSES 
Statistical significance was evaluated using the SPSS statistical programme.  
One way analysis of variance (ANOVA) and post-hoc Bonferroni tests were 
used for multiple comparisons. Student’s T test was used for comparing 
means of two independent groups. Results at p ≤ 0.05 were considered 
statistically significant.  
 
 
 
 
    
 
 
47 
The following table summarizes the most important reagents used in this 
study   
Reagents Company 
1,25-dihydroxyvitamin D3 Leo Pharmaceutical 
3-Amino-9-Ethylcarbazol Sigma-Aldrich 
Actin antibody Santa Cruz 
Cell culture plates Greiner Bio-One 
Cell Death Detection Kit (TUNEL) Roche 
CLU 41D Clone antibody Upstate 
Clusterin-α/ß (H-330) antibody Santa Cruz 
Conventional PCR primers (CLU, 
ß2µglob) 
Tib Mol Biol 
Detection reagent Amersham Biosciences 
FCS PAA Laboratories GmbH 
G-418 Sulphate PAA Laboratories GmbH 
Goat anti-mouse antibody Sigma-Aldrich 
Melanocyte growth medium Promocell 
M-MLV RT H (-) Point Promega 
Omniscript Qiagen 
Permanent Aquatex media MERCK Biosciences 
Real-time RT-PCR primer (CLU: 
HS_CLU_1_SG) 
Qiagen QuantiTech 
Real-time RT-PCR primer (ß2µglob) Tib Mol Biol 
RNAeasy MiniKit Qiagen  
RPMI 1640 PAA Laboratories GmbH 
SYBER Green kit Qiagen 
UV-B lamp Waldmann 
Western blot films Roche 
Western blot membranes Roche  
All other chemicals were of analytical grade 
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3. RESULTS 
 
3.1. CLUSTERIN EXPRESSION IN MELANOMA TISSUES AND CELL 
LINES 
Immunohistochemistry detection of CLU:  
It was the aim of this study to characterize the expression of CLU in 
melanoma tissues and cell lines in order to test whether CLU expression is 
connected to malignant melanoma progression and/or pathogenesis. Hence, 
patient tissues, as described in Materials and Methods, were 
immunohistochemically stained. Immunohistochemistry (IHC) revealed CLU 
staining in a proportion of the malignant melanoma and the metastasis of 
malignant melanoma tissues, but not in acquired melanocytic nevi tissues. 
Positive cases of primary malignant melanomas (n= 5/18) revealed a low or 
moderate CLU immunoreactivity for the H-330 antibody used (Figure 3.1.1.a). 
The staining was homogeneous (in the nuclei and cytoplasm of positive cells). 
There were also no apparent differences comparing the labelling pattern for 
CLU in primary malignant melanoma according to histological type (superficial 
spreading or nodular melanoma) or histological grading. Positive cases of 
metastases of malignant melanoma (n= 3/25) revealed homogeneously low 
nuclear and cytoplasmic immunoreactivity for CLU. All cases of acquired 
melanocytic nevi analyzed (n= 30) were negative for CLU (Figure 3.1.1.b). 
Table 3.1. provides a semi-quantitative analyses of clusterin immunoreactivity 
in melanocytic skin tumours (values for SI, PP, and resulting IRS). The 
epidermal keratinocytes showed no staining of CLU, and neither did the hair 
follicles nor the sebaceous glands. Next, we were interested in the question of 
whether CLU was expressed in melanoma cell lines in the same pattern as in 
the IHC. 
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Figure 3.1.1. (a,b) Immunohistochemical detection of CLU in primary malignant melanoma 
(type: superficial spreading melanoma, case 1 in Table 2.1.). Notice moderate nuclear and 
cytoplasmic staining in positive tumour cells using antibody H330 directed against clusterin-
α/ß (the arrows show the positive CLU staining). (c,d) Immunohistochemical detection of CLU 
was not apparent in acquired melanocytic nevi. Representative images are shown with a 
magnification of 1:100. 
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Table 3.1. Semi-quantitative analysis of clusterin immunoreactivity in melanocytic skin tumours 
Clusterin-α/ß (H-330)  Malignant 
melanoma 
(n=18) 
Metastases of 
malignant 
melanoma (n=25) 
Acquired 
melanocytic nevi 
(n=30) 
0              13                22 30 
1                3                  3  0 
2                2                  0  0 
Staining Intensity (SI)* 
3                0                  0  0 
Mean SI            0.39        0.12  0 
0    13                22 30 
1                2                  3  0 
2                3                  0  0 
Percentage of positive 
cells (PP)** 
3                0                  0  0 
Mean PP            0.45         0.12  0 
Mean Immunoreactivity 
Score (IRS)*** 
           0.18          0.014  0 
*   0= no staining, 1= low staining, 2= moderate staining, 3= strong staining  
** 0= no positive cells, 1= 1-50% positive cells, 2= 51<75% positive cells, 3= >75% positive cells 
*** IRS= SI x PP  
Note that CLU is detected in a proportion of malignant melanomas and metastases of malignant 
melanoma, but not in acquired melanocytic nevi (n= number of samples examined). 
 
 
 
Conventional PCR detection of CLU: 
To test whether CLU mRNA expression in melanoma cell lines was 
comparable to IHC, conventional PCR was used. CLU mRNA was detected in 
all melanoma cell lines analyzed (SK-MEL-28, SK-MEL-25, SK-MEL-5, 
MeWo) and NHM (Figure 3.1.2.). Both CLU and ß2 µglob bands were at the 
expected size corresponding to 200 bp and 250 bp, respectively. However, 
these results were partially in agreement with the IHC results, where nevi 
tissues were negative for CLU expression, and only some cases of malignant 
melanoma showed positive CLU staining. Thus, we sought a quantitative 
technique to assess CLU mRNA levels. 
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Figure 3.1.2. Expression of CLU mRNA in melanoma cells: Conventional PCR gel images 
showing CLU expression in SK-MEL-5, MeWo, SK-MEL-28, and NHM human melanoma cells 
using CLU and β2-µglob primers as described in ‘Materials and Methods’. PCR product sizes 
were 200 bp and 250 bp, respectively. The bands’ sizes were determined by using a step 
ladder 50bp marker in each run. Experiments were done in duplicates. 
 
 
Real-time RT-PCR detection of CLU: 
To answer the question of whether CLU mRNA expression is different in 
melanoma cell lines compared to their 1,25(OH)2D3 sensitivity, two different 
groups of human melanoma cell lines were used, vitamin D-resistant and -
sensitive melanoma cell lines. These cell lines were used to test whether CLU 
expression varies between the cell lines, and also because 1,25(OH)2D3 is an 
agent that is discussed to be of therapeutic use in the treatment of malignant 
melanoma. CLU mRNA was also quantitatively detected using real-time RT-
PCR in all the melanoma cell lines analyzed at various expression levels. 
Vitamin D-resistant melanoma cell lines, SK-MEL-5 and SK-MEL-25 had the 
highest levels of CLU (8 x 10-3 and 8 x 10-4 of normalized ratio, respectively), 
while vitamin D-sensitive melanoma cell lines, MeWo, SK-MEL-28 and normal 
human melanocytes (NHM) had significantly lower levels of CLU (3 x 10-4, 1 x 
10-5 and 2 x 10-4 of normalized ratio, respectively), Figure 3.1.3. The 
normalized ratio represents the ratio between the target gene, in this case, 
CLU, and the corresponding reference gene, and in this case, ß2-µglob. NHM 
had an expression level similar to vitamin D-sensitive melanoma cell lines. 
These results are in agreement with the conventional PCR results, but again 
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only partially in agreement with the IHC staining, where nevi tissues were 
negative for CLU staining.  
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(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.3. Expression of CLU mRNA in various melanoma cell lines: Real-time RT-PCR 
quantitative results showing levels of CLU expression in the various melanoma cell lines 
used. SK-MEL-5, -25 (vitamin D-resistant melanoma cell lines), and MCF (breast cancer cell 
lines) had the highest levels of CLU, while MeWo and SK-MEL-28 (vitamin D-sensitive 
melanoma cell lines) had the lowest levels of CLU expression (a, b). CLU expression is higher 
in vitamin D-resistant as compared to -sensitive melanoma cell lines and NHM (c). The 
normalized ratio represents the ratio between the target gene, in this case, CLU, and the 
corresponding reference gene, and in this case, ß2-µglob. Experiments were performed in 
duplicate and repeated at least twice. Error bars represent the SD. 
 
 
Protein analysis: 
We then sought to confirm the differences in CLU expression on the protein 
level among the melanoma cell lines used. Thus, western blot analyses, using 
a specific CLU antibody, revealed bands at ~80 and ~40 kDa in all melanoma 
cell lines and NHM analyzed; these polypeptide bands represent, sCLU 
protein forms, where cleaved α- and ß- protein smears are apparent and 
mature sCLU protein was also noted, respectively (Figure 3.1.4.). The western 
blot images are in agreement with the real-time RT-PCR results, where the 
sCLU protein bands vary between strong visible bands, to moderate or even 
faint bands in MeWo and SK-MEL-28 (notice the ~ 80 kDa band), 
respectively. Both CLU mRNA and protein are expressed in lower amounts in 
vitamin D-sensitive melanoma cell lines compared to vitamin D-resistant 
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melanoma cell lines. Hence, it was important to elucidate whether CLU 
expression is regulated by 1,25(OH)2D3 treatment.    
 
 
 
 ~ 80 kDa 
 
 ~40 kDa 
 
 
                                        MeWo  MelJuSo  SK-MEL-5                           LNT-1   SK-MEL-28  SK-MEL-25 
   
 
                          
 
 
  Actin                                                                      Actin 
 
Figure 3.1.4. Western Blot analysis showing a double band (80 and 40 kDa) indicating the 
presence of sCLU in the upper panel. CLU expression was detected at various levels, where 
vitamin D-sensitive melanoma cell lines (SK-MEL-28 and MeWo) had lower CLU expression 
as compared to –resistant melanoma cell lines (SK-MEL-5, -25). The lower panels show actin 
levels as a loading control. LNT-1 prostate cell lines were used as a positive control as they 
over-express sCLU. The bands’ sizes were determined by using a prestained protein marker 
in each gel. Experiments were repeated at least twice, and representative images are shown. 
 
 
 
3.2. TIME-DEPENDENT CLU REGULATION IN MELANOMA CELL LINES 
BY 1,25-DIHYDROXYVITAMIN D3  
Different experiments were performed to answer the question of whether CLU 
expression is regulated by 1,25(OH)2D3 treatment due to the fact that 
1,25(OH)2D3 treatment represents a palliative therapy for the metastasis of 
malignant melanoma. The first set of experiments was a colony forming ability 
assay (CFAs). The plating efficiencies (PEs) of cell lines to be analyzed were 
determined before a CFA with 1,25(OH)2D3 were performed. To determine 
PEs, 1,000, 5,000, and 10,000 cells were platted onto 10-cm plates and the 
medium was changed daily for 7 days. Cells were then fixed and stained with 
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crystal violet and counted. Optimal PEs for each cell line was the determined 
and reported in graphic form in Figure 3.2.1. The different melanoma cell lines 
used had different PEs. MeWo had the highest PE. Following that, the PE for 
melanoma cell lines following 1,25(OH)2D3 treatment had to be determined to 
be able to compare with CLU expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1. Plating efficiencies for various cell lines. Analysis of cell proliferation (CFA) in 
some of cell lines used (described in Materials and Methods), showing the number of colonies 
counted after 7 days without any treatment. The various cell lines tested had different PEs. 
 
 
Anti-proliferative effects of 1,25(OH)2D3 were investigated in MeWo (vitamin 
D-sensitive) and SK-MEL-25 (vitamin D-resistant) cells using CFAs (Figure 
3.2.2.a). At 10-6 and 10-7 M, 1,25(OH)2D3 inhibited the growth and proliferation 
of MeWo (70% and 20%, respectively) but not of SK-MEL-25 cells (Figure 
3.2.2.b). The anti-proliferative effects of 1,25(OH)2D3 were dose- and time-
dependent and most pronounced at 10-6 M. Interestingly, after 1,25(OH)2D3-
treatment at a concentration of 10-10 M, the proliferation of MeWo cells was 
increased (~ 40%). This experiment confirms that the human melanoma cell 
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lines we have in culture were indeed either vitamin D-sensitive or -resistant 
melanoma cell lines, as described in the literature (Seifert et al., 2004). 
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(c) 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. Analysis of cell proliferation (colony forming ability assays (CFAs) as described 
in ‘Materials and Methods’) in a vitamin D-responsive (MeWo) and -resistant (SK-MEL-25) 
melanoma cell line following treatment with 1,25(OH)2D3. (a) Number of colonies after 
treatment of MeWo and SK-MEL-25 melanoma cells with different concentrations of 
1,25(OH)2D3 for 7 days. (b) Inhibition of cell proliferation following 1,25(OH)2D3 treatment. 
Individual columns represent the inhibitory rate of colony forming, calculated from percentage 
of colonies counted following 1,25(OH)2D3 treatment as compared to control. Note that MeWo 
cells show dose-dependently an inhibition (10
-6
 M and 10
-7
 M) or an increase (10
-10
 M) of 
proliferation as compared to controls treated with vehicle (ethanol) alone. These effects are 
not observed in SK-MEL-25 cells. Shown are means plus standard deviation, where error 
bars represent SD. (c) Two plates showing the colonies observed following crystal violet 
staining. The left-side plate is MeWo cells treated with 1,25(OH)2D3 10
-6
 M, while the right-
hand one shows those treated with 10
-10
 M. Note that there are more colonies in right-side 
plate (arrows point to some of the colonies on the plates). Experiments were done in 
duplicates and repeated twice. 
 
 
3.2.1. CLU REGULATION IN VITAMIN D-SENSITIVE BUT NOT IN VITAMIN 
D-RESISTANT HUMAN MELANOMA CELL LINES 
 
The second set of experiments to determine whether CLU expression is 
regulated by 1,25(OH)2D3 treatment were performed by measuring CLU 
mRNA expression in treated melanoma cell lines using real-time RT-PCR. 
Real-time RT-PCR showed an increase in CLU mRNA expression after 96 hrs 
of 1,25(OH)2D3 treatment in MeWo, Figure 3.2.1.1.a. The increase was most 
prominent when compared to the expression level at 24 hrs and 72 hrs. This 
increase was not significant (p ≤ 0.1), however, a trend was noted, suggesting 
that an additional analysis at longer times may reveal a slowly increasing 
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expression pattern. In SK-MEL-28 and SK-MEL-5, no differences were 
observed in CLU-mRNA levels following 1,25(OH)2D3 treatment, Figure 
3.2.1.1.b,c. CLU does not seem to be directly regulated by 1,25(OH)2D3 
treatment, nor does CLU expression depend on the PE of the cell lines.  
 
 
(a) MeWo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1.1. CLU mRNA expression in melanoma cell lines (RT-PCR). (a) CLU expression 
in MeWo cells. The expression is shown as a ratio between 1,25(OH)2D3 and EtOH (vehicle) 
treated cells, and the ethanol (control) ratio was adjusted to 1. Note an increase in CLU 
mRNA expression after 96 hrs of treatment. Experiments were performed in duplicates and 
repeated at least twice. Error bars represent SD, and p value ≤ 0.1 is marked with an asterisk.  
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(b) SK-MEL-28 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1.1. CLU mRNA expression in melanoma cell lines (RT-PCR). (b) CLU expression 
in SK-MEL-28. The expression is shown as a ratio between 1,25(OH)2D3 and EtOH (vehicle) 
treated cells, and the ethanol (control) ratio was adjusted to 1. CLU mRNA expression was 
not affected following 1,25(OH)2D3 treatment. Experiments were performed in duplicates and 
repeated at least twice.Error bars represent SD.  
 
(c) SK-MEL-5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1.1. CLU mRNA expression in melanoma cell lines (RT-PCR). (c) CLU expression 
in SK-MEL-5. The expression is shown as a ratio between 1,25(OH)2D3 and EtOH (vehicle) 
treated cells, and the ethanol (control) ratio was adjusted to 1. CLU mRNA expression was 
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not affected following 1,25(OH)2D3 treatment. Experiments were performed in duplicates and 
repeated at least twice. Error bars represent SD. 
 
However, a comparison between the three cell lines (MeWo, SK-MEL-28, and 
-5) at 96 hrs showed a statistically significant (p ≤ 0.05) difference between 
CLU mRNA expression, Figure 3.2.1.2.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.1.2. Comparison between the CLU mRNA expression (shown in an x-fold 
expression ratio of 1,25(OH)2D3  to ethanol) in MeWo, SK-MEL-28, and –5 melanoma cell 
lines after 96 hrs of 1,25(OH)2D3 treatment.    
 
 
3.3. CLU EXPRESSION IN LNCaP PROSTATE CELL LINES 
To better understand the role of CLU for proliferation, cell cycle, and 
apoptosis, we required a cell line that would stably over-express either sCLU 
or nCLU. We were able to attain a suitable cell culture model system using 
LNCaP human prostate cancer cells that over-expressed a stably transfected 
sCLU plasmid vector (LNT-1) as compared to its isogenic counterparts 
(LN/C). Before any experiments could be done and conclusions drawn out, 
the over-expression in LNCaP cells had to be confirmed. The stable 
transfection of sCLU in LNT-1 cells and the presence of sCLU in LN/C cells 
were confirmed using western analysis. As shown in Figure 3.3., two bands 
were obtained at ~80 kDa and 40 kDa, which have been reported previously 
to be characteristic for sCLU. Both bands were much stronger in LNT-1 cells 
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as compared to LN/C cells, clearly demonstrating the over-expression of 
sCLU in LNT-1 cells. In both cell lines used, no bands characteristic for nCLU 
were observed. These findings are in agreement with results reported 
previously (Miyake et al., 2004). 
 
 
                     
                    ~ 80 kDa 
          
                ~ 40 kDa 
   Actin 
                           
                                           
LNT-1    LN/C 
 
Figure 3.3. Western blot showing expression of sCLU protein in LNCaP cells stable 
transfected with sCLU (LNT-1) as compared to empty vector alone-transfected LNCaP cells 
(LN/C). The bands’ sizes were determined by using a prestained protein marker in each gel. 
The over-expression of sCLU is apparent in LNT-1. Actin levels are shown as loading 
controls.  
 
 
3.4. OVER-EXPRESSION OF sCLU MODULATES THE ANTI-
PROLIFERATIVE EFFECTS OF 1,25-DIHYDROXYVITAMIN D3 IN HUMAN 
LNCaP PROSTATE CANCER CELL LINES 
To assess whether sCLU over-expression would protect the cell lines used 
against anti-proliferative effects of 1,25(OH)2D3, a number of experiments 
were carried out.  First, CFA was performed on LNT-1 and LN/C cells to 
evaluate whether sCLU over-expression modulates the anti-proliferative 
effects of 1,25(OH)2D3. LNCaP cells were plated on 10-cm plates, then 
medium and 1,25(OH)2D3 were given daily for 7 days. The colonies were then 
stained and counted. 1,25(OH)2D3 inhibited the growth and proliferation of 
LN/C cells and LNT-1 cells at doses of 10-6 and 10-7 M (53% and 40%, 
respectively) (36% and 2%, respectively), while at 10-10 M, it induced slightly 
pronounced proliferation in both cell lines (the induction of proliferation was 
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87% in LN/C and 25% in LNT-1 cells) (Figure 3.4.a). Differences comparing 
both cell lines were most prominent after treatment with 1,25(OH)2D3 at a 
dose of 10-7 M (P = 0.081), although this effect was not statistically significant. 
sCLU over-expression also protected slightly against the proliferation-inducing 
effects of 1,25(OH)2D3 at the 10
-10 M in LNT-1 cells. This effect was also not 
statistically significant, but rather a trend. Thus, sCLU over-expression does 
not protect against the anti-proliferative effects of 1,25(OH)2D3. 
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(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. 1,25(OH)2D3 modulates proliferation in prostate cancer cells (LNCaP) that are 
stable transfected with and over-express sCLU (LNT-1) and in control vector-transfected cells 
(LN/C) (CFA). (a) Number of colonies after treatment of LNT-1 and LN/C with different doses 
of 1,25(OH)2D3 after 7 days (10
-6
 M, 10
-7
 M, and 10
-10
 M). (b) Inhibition of cell proliferation 
following 1,25(OH)2D3 treatment. Individual columns represent the inhibitory rate of colony 
forming, calculated from percentage of colonies counted following 1,25(OH)2D3 treatment as 
compared to controls. Error bars correspond to SD. p value ≤ 0.1 is marked with an asterisk.   
 
 
3.5. OVER-EXPRESSION OF sCLU MODULATES THE PROAPOPTOTIC 
EFFECTS OF 1,25-DIHYDROXYVITAMIN D3 IN HUMAN LNCaP 
PROSTATE  CANCER CELL LINES 
Next, we tested if sCLU over-expression would protect against 1,25(OH)2D3-
induced apoptosis. TUNEL analysis was used to compare apoptosis in LNT-1 
versus LN/C following treatment with 1,25(OH)2D3 at different doses (10
-6 M, 
10-7 M, 10-10 M) according to the manufacturer’s instructions, and apoptosis 
was measured using FACscan. As shown in Figure 3.5., daily 1,25(OH)2D3 
treatment induced more apoptosis in LN/C as compared to LNT-1 after 72 hrs 
in all doses used. The effect was most prominent at 10-7 M (p= 0.093), (10% 
apoptosis induction in LN/C as compared to 5% in LNT-1 cells). However, this 
effect was statistically not significant. The following question was whether 
sCLU over-expression would protect against the effects of other apoptosis-
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inducing agents, since it has been reported that sCLU over-expression 
protects against H2O2, for example (Miyake et al., 2004). 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. LN/C cells are more sensitive to 1,25(OH)2D3-induced apoptosis as compared to 
LNT-1 cells (TUNEL assay) (a) Percentage of apoptotic cells (LNT-1 and LN/C cells) following 
72 hrs of 1,25(OH)2D3 treatment (10
-6
 M, 10
-7
 M, and 10
-10
 M). (b) The percentage of apoptotic 
cells (LNT-1 and LN/C cells) in the control group is subtracted from percentage of apoptotic 
0
5
10
15
20
25
30
35
Ethanol
control
10-6 M 10-7 M 10-10 M
1,25(OH)2D3 concentration
p
e
rc
e
n
ta
g
e
o
f 
a
p
o
p
to
s
is
 (
%
)
LNT-1
LN/C
*
-5
0
5
10
15
20
25
30
LNT-1 LN/C
10-6 M
10-7 M
10-10 M
p
e
rc
e
n
ta
g
e
 o
f 
a
p
o
p
to
s
is
 (
%
) 
cell lines
*
    
 
 
65 
cells following treatment with 1,25(OH)2D3. Error bars correspond to standard deviation, and 
P value ≤ 0.1 is marked with an asterisk. 
 
 
3.6. OVER-EXPRESSION OF sCLU MODULATES THE CYTOTXIC 
EFFECTS OF UV-B IN HUMAN LNCaP PROSTATE CANCER CELL LINES 
To address the question of whether sCLU over-expression protects LNCaP 
cell lines against other apoptosis-inducing agents, for example, UV-B; CFA 
was performed. Anti-proliferative effects of UV-B were investigated in LNT-1 
and LN/C cells using CFA, as described before. Following 100 J/m2 
irradiation, the growth of both cell lines was inhibited (~ 60%). However, 
following higher doses of irradiation, 500 J/m2, the cells’ growth was almost 
100% inhibited. There were no differences between the two cell lines with 
regard to sCLU over-expression, Figure 3.6.1. sCLU over-expression did not 
protect against UV-B-induced antiproliferative effects. 
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(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.1. UV-B modulates proliferation in prostate cancer cells, LNT-1 and LN/C. (a) 
Number of colonies after UV-B exposure with different joules after 7 days. (b) Inhibition of 
proliferation following UV-B exposure. Individual column represent the inhibitory rate of colony 
forming, calculated from the percentage of colonies counted following UV-B exposure as 
compared to controls. Error bars represent SD. 
 
 
Then, we checked the apoptotic effects of UV-B on LNCaP cell lines, and how 
would sCLU over-expression change the outcome. TUNEL analysis was used 
to compare apoptosis in LNT-1 versus LN/C following treatment with UV-B at 
different doses (0 J/m2, 100 J/m2, 500 J/m2). As shown in Figure. 3.6.2., UV-B 
treatment induced more apoptosis in LN/C as compared to LNT-1 after 72 hrs 
in all doses used. The effect was statistically significant in the percentage of 
apoptotic cells at 500 J/m2 (p= 0.038), (~7% apoptosis induction in LNT-1 as 
compared to ~17% in LN/C cells). sCLU over-expression protected LNT-1 
cells against UV-B-induced apoptosis. Finally, we sought to analyze whether 
sCLU over-expression has any effects on the cell cycle regulation, as this 
issue is a controversial one in the literature (Bettuzzi et al., 2002, Criswell et 
al., 2003).  
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(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.2. LN/C cells are more sensitive to UV-B induced apoptosis as compared to LNT-1 
cells (TUNEL assay). (a) Percentage of apoptotic cells following 72 hrs of UV-B exposure 
(100 J/m
2
, 500 J/m
2
). (b) The percentage of apoptotic cells in the control group is subtracted 
from the percentage of apoptotic cells following UV-B exposure. Error bars represent the SD, 
and p value ≤ 0.05 is marked with an asterisk. 
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3.7. OVER-EXPRESSION OF sCLU DOES NOT AFFECT THE CELL 
CYCLE FOLLOWING 1,25-DIHYDROXYVITAMIN D3 TREATMENT OR UV-
B IRRADIATION 
Following cell cycle analysis on LNCaP cells that were either treated with 
1,25(OH)2D3 (vehicle ethanol, 10
-6 M, 10-7 M) or with UV-B (0 J/m2, 100 J/m2, 
500 J/m2), no changes were noted in the cell cycle. There were no effects on 
the cell cycle regulation with respect to sCLU over-expression. The cell cycle 
was analyzed after 24, 48, and 72 hrs of 1,25(OH)2D3  treatment, and 9, 12, 
15, 18, 21, and 24 hrs of UV-B irradiation. The difference between the time 
points is due to the fact that cells respond to the effects of UV-B earlier than 
those of 1,25(OH)2D3 Figures 3.7.1 and 3.7.2. These results show that sCLU 
over-protection does not affect the cell cycle regulation following either 
1,25(OH)2D3  or UV-B exposures. 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
24 48 72
G2 S
G1 G2 S
G1LNT-1:
LN/C:
p
e
rc
e
n
ta
g
e
 o
f 
c
e
ll
s
 (
%
)
(hrs)
    
 
 
69 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.1. Cell cycle analysis of LNCaP cells following 1,25(OH)2D3 treatment. (a) sCLU 
over-expression did not affect the cell cycle regulation in stable transfected cells, LNT-1, 
compared to the isogenic cell, LN/C, when treated with 1,25(OH)2D3 [10
-6
 M] (b) sCLU over-
expression also did not affect the cell cycle regulation in stable transfected cells, LNT-1, 
compared to the isogenic cell, LN/C, when treated with 1,25(OH)2D3 [10
-7
 M] 
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(b) 
 
 
Figure 3.7.2. Cell cycle analysis of LNCaP cells following UV-B irradiation. (a) sCLU over-
expression did not induce any changes in cell cycle in the stable transfected cells, LNT-1, 
compared to the isogenic cell, LN/C, when exposed to a UV-B does of 100 J/m
2
 (b) sCLU 
over-expression did not induce any changes in cell cycle in the stable transfected cells, LNT-
1, compared to the isogenic cell, LN/C, when exposed to a UV-B does of 500 J/m
2
. 
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4. DISCUSSION 
 
An increasing body of evidence points to a contribution of CLU to the 
progression of several cancers, including kidney carcinoma (Evans et al., 
1988; Matuda et al., 2003), anaplastic large cell lymphoma (Seiberg et al., 
1995), ovarian cancer (Thomas-Salgar et al., 1994), breast tumours (van 
Weelden et al., 1998; Leskov et al., 2003; July et al., 2004), prostate cancer 
(Miyake et al., 2000, 2004; Bettuzzi et al., 2002; Zellweger et al., 2002) and 
colon tumours (Chen et al., 2003; Pucci et al., 2004). However, the exact roles 
of CLU in pathogenesis and progression of cancer are still not well defined. 
For example, the role of CLU in malignant melanoma has yet to be defined. 
UV-B-induced apoptosis has been discussed to represent an important factor 
for the pathogenesis of malignant melanoma, and as described in the 
introduction section, CLU is a key regulator of apoptosis. Thus, one goal of 
our study was to examine the role of CLU in the sensitivity of malignant 
melanoma cells to cytotoxic agents, UV-B and 1,25(OH)2D3 exposures. 
In this work, we show that CLU is expressed in melanoma tissues and 
melanoma cell lines. The presence of CLU in a proportion of primary 
cutaneous malignant melanomas, but not in benign melanocytic nevi, 
indicates that CLU may be of importance in the pathogenesis of malignant 
melanoma. Expression of CLU in melanoma has been analyzed recently by 
another group using a different immunohistochemical technique in a much 
lower number of cases as compared to our study (Hoeller et al., 2005). 
Antigen retrieval by cooking in citrate buffer, and staining using the LSAB kit 
were among the differences in the immunohistochemical techniques used by 
Hoeller et al., compared to our study. These researchers found low levels of 
CLU expression in all their nevi tissues examined, except for 18% of the 
cases where high CLU expression was noted. In contrast, 40% of the primary 
melanomas analyzed in their study exhibited high CLU expression levels 
(Hoeller et al., 2005).  Thus, their study supports our results where we 
demonstrated, with a significant number of patient samples, that CLU protein 
was significantly increased in primary cutaneous malignant melanomas 
compared to benign nevi. However, the mechanisms that underlie this 
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increased expression of CLU in melanomas as compared to nevi are 
presently unknown, as will be discussed below.  
In our study we also assessed whether changes in CLU expression may be 
associated with progression from primary cutaneous malignant melanoma to 
cutaneous or lymph node metastases. Our immunohistochemical studies did 
not reveal differences comparing CLU immunoreactivity in primary cutaneous 
malignant melanomas (IRS = 0.18) and metastases (IRS = 0.014). These data 
could suggest that sCLU expression is elevated early in melanoma 
carcinogenesis, and thereby is not elevated as cells progress to metastatic 
states. Nevertheless, these data do not support the concept, that CLU 
expression may be associated with the progression from primary cutaneous 
malignant melanoma to cutaneous or lymph node metastases. Our results do, 
however, conflict with the work of Hoeller et al. (Hoeller et al., 2005). These 
researchers found elevated CLU expression in 40% of cases with primary 
melanomas and in 60% of melanoma metastases and concluded that CLU 
expression was elevated in the course of melanoma disease progression 
(Hoeller et al., 2005). Partial discrepancies between our results and the study 
of Hoeller et al., may be explained by differences in the immunohistochemical 
techniques used or by differences in the evaluation of the CLU staining (Table 
3.1. was used in our staining evaluation). Finally, differences in our results 
may be related to the much higher case numbers in our study as compared to 
the study of Hoeller et al., wherein a statistical power advantage favours our 
results.  
Expression of certain genes (e.g., CLU) might, generally, be the result of 
elevated rate of transcription, stability of mRNA, elevated protein synthesis or 
increased protein stability. These features can not be analyzed in tumour 
tissues, and therefore, cell culture models are used. When then examined 
CLU mRNA expression in cultured melanocytes in vitro, our real-time RT-PCR 
data revealed increased levels of CLU mRNA expression in melanoma cell 
lines (that were derived from metastases of malignant melanomas) as 
compared to NHM. CLU protein expression was also documented using 
western blot techniques, where two bands representing the sCLU were 
observed. No bands showing the ~ 55 kDa nCLU isoform were observed in 
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any of the melanoma cell lines (the antibody used here detects both CLU 
isoforms. Personal communications, Prof. Bettuzzi, Dipartimento di Medicina 
Seperimentale, Universita di Parma, Italy). To our knowledge, there are no 
studies comparing CLU mRNA expression in between melanoma cells, 
however, our western blot results are in agreement with Hoeller et al., where 
no nCLU protein isoform was seen in the western blot performed by these 
researchers in the melanoma cell lines used, but the band thickness/visibility 
(protein) varied according to the cell line tested (Hoeller et al., 2005). Since it 
is not possible to culture cells from primary melanomas (the whole tissue is in 
general needed for histopathological analyses) and human melanoma cell 
lines can be altered by growth in tissue culture and the selection of growth 
advantages in this environment, these results do not allow a conclusion 
whether increased CLU mRNA levels in melanoma cell lines compared to 
NHM are the result of an up-regulation of CLU during the development from 
nevi to primary melanoma. Nor so they offer insight in understanding the role 
of sCLU during the progression of primary melanoma to metastasizing 
melanoma in vivo. However, our results are in agreement when compared to 
other studies assessing CLU mRNA expression (mostly determined using 
real-time RT-PCR). CLU mRNA levels were increased in tumour cells when 
compared to their normal counterparts in prostate cancer (Miyake et al., 2002, 
2004; Zellweger et al., 2002, 2003), breast carcinoma (Van Weelden et al., 
1998; Leskov et al., 2003), lung cancer (July et al., 2004) and colon cancer 
(Pucci et al., 2004). Some of these researchers were able to draw conclusions 
supporting the theory that increased CLU mRNA levels are associated with 
the progression of certain tumours like prostate cancer (Miyake et al., 2004) 
and colon cancer (Pucci et al., 2004). Furthermore, increases CLU protein 
levels correlated with the aggressiveness of breast tumours (Trougakos et al., 
2004). Some studies have highlighted the importance of CLU as a prognostic 
factor in breast (Redono et al., 2002) and colon (Pucci et al., 2004) cancers. 
Our results do not support the hypothesis that CLU may be an important 
prognostic marker for malignant melanoma. 
The discrepancy between the immunohistochemistry (no CLU staining was 
detected in nevi) and the PCR as well as real-time RT-PCR results (CLU 
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mRNA was detected in NHM), may be due to the differing sensitivities of the 
techniques used for the detection of CLU expression in situ (IHC) as 
compared to in vitro analyses (i.e., using PCR and real-time RT-PCR). 
Another reason may be the difference in the cell proliferation rates in tissues 
compared to the melanoma cells grown in vitro.  
An isoform shift from the expression of nCLU to sCLU was reported and 
theorized to be important for progression of various malignancies, including 
colon cancer (Pucci et al., 2004). Also, over-expression of CLU was closely 
associated with disease progression in bladder cancer (Miyake et al., 2001) 
and prostate cancer acceleration (Miyake et al., 2004). While nCLU is mostly 
found in the nucleus, sCLU is present in the cytoplasmic cell compartment 
(reviewed in Shannan et al., 2006, b). Therefore, we evaluated the 
immunohistochemical staining pattern in primary cutaneous malignant 
melanomas and metastases to assess any differences between nuclear and 
cytoplasmic staining patterns in the progression of malignant melanoma and 
whether these differences could be detected. There were no detectable 
differences between nuclear (nCLU) and cytoplasmic (sCLU) CLU staining. 
Thus, our immunohistochemical results do not support the hypothesis that a 
pattern shift of CLU isoforms may be of importance during progression of 
malignant melanoma. A major caveat in our interpretation of these data is that 
we did not have a positive control for nCLU expression and therefore we can 
not be completely certain we were detecting nuclear versus secretory CLU 
expression in the samples examined in our study. Based on the above, we 
document that both CLU mRNA and protein expressions vary in human 
melanomas and melanoma cell lines, however, unlike other tumours, CLU 
expression does not seem of importance for the progression and/or 
pathogenesis of malignant melanoma.  
Nuclear CLU expression (nCLU) has been shown to be involved in DNA 
repair, at least via Ku70-dependent mechanisms (Yang et al., 1999), where 
nCLU binds to Ku70 forming a trimeric complex with Ku80, and directly affects 
DSB repair. It is well known that up-regulation of DNA repair pathways is 
associated with the pathogenesis of various malignancies, including malignant 
melanoma (Shpitz et al., 2005). Therefore, increased CLU expression in 
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malignant melanoma may be related to the genetic instability in these tumour 
cells and that may stimulate DNA repair pathways. Other authors have 
speculated whether CLU expression in malignant tumours may be related to 
the proliferative activity of tumour cells (Pucci et al., 2004). Therefore, 
increased expression of CLU in malignant melanomas may be related to 
increased proliferative activity. However, when the proliferative activity of 
malignant melanomas was analyzed immunohistochemically, data reported 
were conflicting (Li et al., 2000; Gimotty et al., 2005; Ilmonen et al., 2005). 
Most studies did not report a strong increase in the expression of markers 
associated with cellular proliferation, including Ki-67 and proliferating cell 
nuclear antigen (PCNA) (Ilmonen et al., 2005). Thus, when we compared CLU 
expression in NHM and melanoma cell lines, no correlation of CLU expression 
with proliferative activity was found, as evaluated using CFA, where a fast 
proliferating cell line did not express higher CLU mRNA levels in the real-time 
RT-PCR than lower replicating cell lines examined. This is in agreement with 
the data of Criswell et al., where the expression of sCLU was not related to 
proliferation (Criswell et al., 2003). These data were confirmed in all 
melanoma cells examined in our study, where we also showed that the 
proliferative activity of human melanoma cell lines did not correlate with CLU 
mRNA expression. In summary, the results of our study (IHC and real-time 
RT-PCR) and data reported in the literature do not support the hypothesis that 
increased CLU expression in malignant melanoma may be related to the 
increased proliferative activity in these tumours. A limitation to our elucidation 
of these data is, again, the differences in techniques used between IHC and 
cell culture, where CLU levels of expression are, simply, different.  
UV-B radiation is recognized as a well known external risk factor for the 
development of melanoma, especially lentigo maligna melanoma that affects 
the chronically sun-exposed facial area. UV-B plays a critical role in the 
aetiology of human melanoma, and is involved in initiation and promotion of 
the multi-step carcinogenesis in melanoma (Zhang et al., 2003). UV-B 
exposure induces apoptosis in human melanoma cells via down-regulation of 
bcl-2 and activation of caspase-mediated apoptotic pathways (Zhang et al., 
2003). These two opposing functions of UV-B (risk factor for melanoma, and 
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apoptosis-inducing agent in melanoma cells) could be explained by the doses 
of UV-B, the exposure time, and the frequency of exposure. Although both cell 
cycle and apoptosis changes have been suggested to play essential roles in 
the carcinogenesis of melanoma, the basic mechanisms behind the 
photocarcinogenesis of UV-induced melanomas are still not fully understood 
(Zhang et al., 2003; Yamazaki et al., 2005).  
To better understand the role of CLU in UV-induced changes in cancer 
progression and apoptosis, we required a cell line that would stably over-
express sCLU, the cytoprotective isoform. We were able to obtain a suitable 
cell culture model system using LNCaP human prostate cancer cells that 
over-expressed a stably transfected sCLU plasmid vector (LNT-1) as 
compared to its isogenic counterparts (LN/C). Using these cells, we were able 
to asses the general response mechanism following exposure to either 
1,25(OH)2D3 or UV-B, as discussed below. Proliferation rate, apoptosis, and 
cell cycle changes were evaluated in LNT-1 versus LN/C following UV-B 
exposure. CFA analyses showed that proliferation in both cell lines was 
reduced following UV-B irradiation. However, sCLU did not provide any 
protection against the anti-proliferative effects of UV-B, since both cell lines 
showed comparable responses against the anti-proliferative effects of thus 
type of radiation. UV-B induced anti-proliferative effects have been linked to 
damage-induced cell cycle checkpoint responses (Reagan-Shaw et al., 2006). 
We also demonstrated that UV-B induced dramatic increases in sub G1 cells 
both in LNT-1 and LN/C cells. However, cell cycle analyses of LNT-1 and 
LN/C following various doses of UV-B irradiation showed no significant 
differences between the two cell lines. It is important to note here that the 
higher dose of UV-B used was 500 J/m2, and at this dose, floating/dead cells 
were seen in the medium before the cells were handled. This could explain 
the similar responses of the cell lines at 500 J/m2 in CFA, and cell cycle 
analysis. The role of CLU expression in cell cycle regulation has been 
controversial. CLU over-expression in immortalized human prostate epithelial 
cells resulted in an increased accumulation of the cells at the G0/G1 phases of 
the cell cycle, accompanied by a slow down of the cell cycle progression and 
a reduction of DNA synthesis (Bettuzzi et al., 2002). CLU over-expression 
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also resulted in DNA damage accumulation in human LNCaP prostate cells, 
and helped accelerate prostate cancer development. This is thought to have 
occurred, at least in part, through the inhibition of membrane damage induced 
by H2O2 (Miyake et al., 2004). High levels of nCLU were reported to cause G1 
cell cycle arrest in distinct cell types (Yang et al., 1999). 
Other groups denied an important role of CLU for cell cycle regulation 
(Criswell et al., 2003). Where Criswell et al., found that sCLU was 
transcriptionally repressed by functional p53 independent of the cell cycle, and 
loss of functional p53 appeared to relieve negative regulation on the IR-
induction responses of the CLU gene in a variety of cell types. It can be 
speculated, that either the effects of sCLU over-expression on the cell cycle 
are not a general mechanism, but mediated through certain pathways 
depending on the apoptosis-inducing agent used, or that sCLU does not 
regulate the cell cycle. Our results favour the last speculation, and do not 
support the hypothesis that sCLU exerts profound changes on cell cycle 
regulation in melanoma or in human prostate cancer cells before or after UV-B 
irradiation. 
In contrast to its lack of affects on cell cycle regulation and proliferation, sCLU 
over-expression dramatically protected cells against UV-B-induced apoptosis 
(TUNEL analyses). The protection was statistically significant (p ≤ 0.05) as 
measured 72 hrs following a 500 J/m2 dose. High doses of UV-B induce 
blockage of DNA replication which causes DSBs in the cells, and as 
mentioned above, nCLU is important for DNA-PK. It had been proposed that 
nCLU induces apoptosis by freeing Bax protein, which would normally bind to 
Ku70, then nCLU would bind to Ku70 and inhibit Ku70/Ku80 binding activity 
(Yang et al., 1999; Leskov et al., 2001). This nCLU/Ku70 interaction may 
undergo changes when sCLU is over-expressed, making it possible for cells 
to repair themselves rather than go into apoptosis. This would explain the 
‘lower-than-expected’ percentage of apoptosis in TUNEL analyses. Another 
reason could be, as mentioned previously, that cells were already apoptotic 
upon measurement following a 500 J/m2 UV-B dose. sCLU-mediated 
protection against apoptosis has been reported in the literature against many 
different stimuli (Miyake et al., 2004). Also, it has been speculated that tumour 
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cell survival is associated with over-expression of sCLU and loss of nCLU 
(Pucci et al., 2004). CLU was also proposed to exert anti-apoptotic or pro-
apoptotic functions by interacting with different proteins depending on its 
distribution (Zhang et al., 2005). The mechanisms that underlie this function 
are not well understood and mainly include: CLU regulation by B-MYB 
(Cervellera et al., 2000), NF-κB (Sankilli et al., 2003), IGF-1 (Criswell et al., 
2005) and p53 (Criswell et al., 2003). Our results point to an important role of 
sCLU in protecting cells against UV-B-induced apoptosis. 
CLU has been shown to be of importance for the therapeutic outcome and the 
response to various treatment modalities in a broad range of different 
malignancies (Beer et al., 2005). In this respect, the expression of sCLU in 
tumour cells and its putative counteracting affects against the apoptosis-
inducing capacity of chemotherapeutics has been suggested to be of 
particular importance. Therefore, we investigated the role of CLU on the cell 
death responses of human prostate and melanoma cells to 1,25(OH)2D3, an 
agent that has been shown to induce apoptosis in tumour cells and that is at 
the moment under clinical investigation for the treatment of various types of 
cancers (Osborne and Hutchinson, 2002; Beer et al., 2005). 1,25(OH)2D3 and 
its analogues have been shown to inhibit cell proliferation in a variety of 
preclinical models of cancer, including human prostate cancer. These 
preclinical findings have promoted the clinical use of 1,25(OH)2D3 and its 
analogues for cancer treatment (Beer et al., 2005). Additionally, as pointed out 
in the introduction, preliminary data reported in the literature indicate that CLU 
expression may be directly up-regulated in response to 1,25(OH)2D3 exposure 
(Simboli-Campbell et al., 1996). 
It was previously demonstrated that the introduction of full-length CLU cDNA 
into LNCaP cells increases resistance to apoptosis induced by TNF-α 
treatment (Miyake et al., 2000). Increased expression of CLU in prostate 
cancer is closely correlated with higher Gleason score and cancer progression 
(Miyake et al., 2000). Thus, silencing CLU has been considered a promising 
target for prostate cancer treatment. In several studies, CLU antisense 
oligonucleotides increased the cytotoxic effects of paclitaxel, reducing the IC50 
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of PC3 cells by 75%-90% compared to paclitaxel alone (reviewed in Shannan 
et al., 2006, b).  
To analyze whether CLU expression in melanoma cell lines was regulated by 
1,25(OH)2D3, we tested various human melanoma cell lines that were 
previously characterized to be resistant or sensitive against the anti-
proliferative effects of vitamin D analogues (Seifert et al., 2004). Real-time 
RT-PCR revealed different levels of CLU mRNA in the human melanoma cell 
lines tested. The vitamin D-sensitive melanoma cell lines, MeWo and SK-
MEL-28, had the lowest levels of CLU mRNA as compared to vitamin D-
resistant, SK-MEL-5 and SK-MEL-25, melanoma cell lines. Thus, the basal 
levels of CLU mRNA expression were higher in the vitamin D-resistant 
melanoma cell lines compared to non-isogenic sensitive cell lines. 
Furthermore, NHM expressed similar CLU mRNA expression levels as vitamin 
D-sensitive melanoma cell lines (mainly MeWo). Vitamin D-resistant cell lines 
were reported to have a functional defect in vitamin D receptor-mediated gene 
transcription (Seifert et al., 2004), while -sensitive cell lines and NHM cells 
showed no such vitamin D receptor defect. We speculate that a functional 
vitamin D system acts either directly on CLU expression and suppresses its 
levels as compared to a defect one, or indirectly by suppressing cell 
proliferation and thus CLU expression.  
Additionally, we analyzed the affects of 1,25(OH)2D3 treatment on CLU 
expression in melanoma cell lines. Previous studies demonstrated that 
1,25(OH)2D3 inhibited malignant cell invasion and tumour-induced neo-
angiogenesis by inducing apoptosis (e.g., in breast, prostate and colon 
cancers) (Osborne and Hutchinson, 2002), and modulated growth and 
apoptosis in melanoma cells (Danielsson et al., 1998; Osborne and 
Hutchinson, 2002). Using CFAs, we demonstrated that at high 1,25(OH)2D3 
concentrations (10-6 M or 10-7 M), the proliferation of vitamin D-sensitive cells 
(MeWo) was inhibited. These effects were not observed in vitamin D-resistant 
melanoma cells (SK-MEL-25). Interestingly, using real-time RT-PCR, 
1,25(OH)2D3-treated (10
-6 M) vitamin D-sensitive cells (MeWo) showed up-
regulation of CLU mRNA level (~1.5 fold induction) after 96 hrs. This up-
regulation was a trend (p ≤ 0.1) compared to the CLU mRNA levels after 24 
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hrs. In contrast, vitamin D-resistant cells (SK-MEL-5) showed no such up-
regulation after 1,25(OH)2D3 treatment. Comparison between the three cell 
lines tested (MeWo, SK-MEK-28, and -5), a statistically significant difference 
in CLU mRNA expression following 96 hrs of 1,25(OH)2D3 treatment was 
observed. 
Nevertheless, based on real-time RT-PCR results, 1,25(OH)2D3 treatment 
does not appear to induce up-regulation of CLU mRNA expression (in two 
melanoma cell line out of three used), and increases in the levels of 
expression appear to be independent of the basal CLU mRNA expression. In 
western blot analyses, the up-regulation could not be confirmed due to the low 
expression levels of CLU (as shown in real-time RT-PCR). This leaves us with 
two hypotheses: (1) Real-time RT-PCR primers measure total CLU mRNA 
(both isoforms, sCLU and nCLU), and since nCLU was not detected in the 
western blot for unstressed melanoma cell lines, it can be assumed that the 
basal levels of CLU mRNA are those of sCLU. However, when the cells are 
under stress (e.g. after 1,25(OH)2D3 treatment), and based on previous 
studies, nCLU might be produced. Thus, the increase of CLU mRNA in MeWo 
could be that of nCLU rather than sCLU, especially that after 48 hrs of 
1,25(OH)2D3 treatment where floating cells were observed in the cell culture 
indicative of apoptotic responses. However, nCLU was not up-regulated in 
SK-MEL-28 and SK-MEL-5 cells, and the reason behind this remains to be 
elucidated.  
(2) It is known that more than half of all human tumours contain p53 
mutations, and in most malignancies, mutations in p53 lead to a shutdown of 
p53 tumour suppressor signalling pathway (Ho and Li, 2005). Previous studies 
have shown that MeWo has a single p53 point mutation in codon 341 (Ho and 
Li, 2005). SK-MEL-28 also contains a single p53 point mutation in codon 145, 
and over-expresses mutant p53 (Girnita et al., 2000). SK-MEL-5 exhibits no 
p53 mutations, but it has a functionally aberrant p53, due to the absence of 
p21Waf1, that is also over-expressed (Girnita et al., 2000). As mentioned in the 
introduction, p53 can suppress basal as well as ionizing radiation-induced 
sCLU expression in breast and colon cell lines by repressing CLU promoter 
activity and transcription (Criswell el al., 2003). Also, sCLU expression was 
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shown to be regulated by IGF-1 signalling, and since IGF-1 is thought to be a 
factor in tumorigenesis, it is possible that melanomas over-express IGF-1. 
Thus, based on our results and what is reported in the literature, it is possible 
that CLU up-regulation depends on the type and place of the point mutation in 
the investigated cell lines through the IGF-1 signalling pathway. Since these 
melanoma cell lines express either mutations in p53, or have a functionally 
aberrant p53 and it (p53) regulates IGF-1 ligand expression, which in turn, 
regulates sCLU expression (Dr. Boothman, personal communications), it can 
be hypothesized that the increase in sCLU expression in malignant melanoma 
might be due to p53 mutations. Thus, in this context, tumour formation might 
depend on the distorted interaction between p53 and sCLU.    
However, it is still possible that the increase in CLU expression may be of 
importance for 1,25(OH)2D3-mediated biological responses in melanoma cells, 
including anti-proliferative effects and apoptosis. It remains to be elucidated 
whether the modulation of CLU expression may be involved in the anti-tumour 
effects of 1,25(OH)2D3 as well. Furthermore, it has been previously reported 
that MeWo is characterized as a high invasive melanoma cell lines, while SK-
MEL-28 as a low invasive cell line (Billion et al., 2006), and since different 
levels of CLU mRNA were reported in non-treated melanoma cell lines, our 
results point to the fact that CLU expression may be related to the aggressive 
and invasive status of melanoma, and thus to the pathogenesis of 
melanomas.  
To evaluate the effects of 1,25(OH)2D3 on sCLU over-expression, the LNCaP 
human prostate cancer cells (LNT-1 and LN/C) were treated with 1,25(OH)2D3 
to test for differences in the anti-proliferative and apoptotic effects exerted by 
over-expression of sCLU. CFA and TUNEL analyses revealed that both cell 
lines show anti-proliferative and apoptotic effects following 1,25(OH)2D3  
treatment, respectively. Nevertheless, sCLU over-expression did not protect 
against the anti-proliferative and apoptotic effects of 1,25(OH)2D3, (p ≤ 0.1 
representing a trend). Cell cycle analyses showed no differences between the 
two cell lines before and after 1,25(OH)2D3 exposure.   
In conclusion, following UV-B exposure, sCLU only provides protection 
against UV-B-induced apoptosis, but not against -induced anti-proliferative 
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effects. On the other hand, sCLU provided no significant protection (only a 
trend with p< 0.1) against 1,25(OH)2D3-induced apoptosis and anti-
proliferative effects. 
 
Future research regarding CLU and malignant melanoma should include 
silencing sCLU expression and then assessing how melanoma cell lines 
would respond to various cytotoxic agents, screening and sequencing the 
CLU gene for any mutations in human melanoma cell lines, and assessing the 
IGF-1 signalling pathway in melanoma cell lines (since it regulates sCLU 
expression). Furthermore, to overcome the problem in our 
immunohisochemical analyses of the positive control of nCLU, this truncated 
form (nCLU) could be over-expressed in human melanoma cell lines then 
used as a positive control.   
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